Plethysmographic respiration rate detection

Information

  • Patent Grant
  • 10098550
  • Patent Number
    10,098,550
  • Date Filed
    Monday, April 11, 2016
    8 years ago
  • Date Issued
    Tuesday, October 16, 2018
    6 years ago
Abstract
A plethysmographic respiration processor is responsive to respiratory effects appearing on a blood volume waveform and the corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate. A preprocessor identifies a windowed pleth corresponding to a physiologically acceptable series of plethysmograph waveform pulses. Multiple processors derive different parameters responsive to particular respiratory effects on the windowed pleth. Decision logic determines a respiration rate based upon at least a portion of these parameters.
Description
BACKGROUND OF THE INVENTION

Pulse oximetry is a widely accepted noninvasive procedure for measuring the oxygen saturation level of arterial blood, an indicator of a person's oxygen supply. A typical pulse oximetry system utilizes an optical sensor clipped onto a fingertip to measure the relative volume of oxygenated hemoglobin in pulsatile arterial blood flowing within the fingertip. Oxygen saturation (SpO2), pulse rate and a plethysmograph waveform, which is a visualization of pulsatile blood flow over time, are displayed on a monitor accordingly.


Conventional pulse oximetry assumes that arterial blood is the only pulsatile blood flow in the measurement site. During patient motion, venous blood also moves, which causes errors in conventional pulse oximetry. Advanced pulse oximetry processes the venous blood signal so as to report true arterial oxygen saturation and pulse rate under conditions of patient movement. Advanced pulse oximetry also functions under conditions of low perfusion (small signal amplitude), intense ambient light (artificial or sunlight) and electrosurgical instrument interference, which are scenarios where conventional pulse oximetry tends to fail.


Advanced pulse oximetry is described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo Corporation (“Masimo”) of Irvine, Calif. and are incorporated by reference herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, which are also assigned to Masimo and are also incorporated by reference herein. Advanced pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO2, pulse rate (PR) and perfusion index (PI) are available from Masimo. Optical sensors include any of Masimo LNOP®, LNCS®, SofTouch™ and Blue™ adhesive or reusable sensors. Pulse oximetry monitors include any of Masimo Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.


Advanced blood parameter measurement systems are described in at least U.S. Pat. No. 7,647,083, filed Mar. 1, 2006, titled Multiple Wavelength Sensor Equalization; U.S. patent application Ser. No. 11/367,036, filed Mar. 1, 2006, titled Configurable Physiological Measurement System; U.S. patent application Ser. No. 11/367,034, filed Mar. 1, 2006, titled Physiological Parameter Confidence Measure and U.S. patent application Ser. No. 11/366,208, filed Mar. 1, 2006, titled Noninvasive Multi-Parameter Patient Monitor, all assigned to Masimo Laboratories, Irvine, Calif. (Masimo Labs) and all incorporated by reference herein. Advanced blood parameter measurement systems include Masimo Rainbow® SET, which provides measurements in addition to SpO2, such as total hemoglobin (SpHb™), oxygen content (SpOC™), methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSposable™ and reusable sensors. Advanced blood parameter monitors include Masimo Radical-7™, Rad-87™ and Rad57™ monitors, all available from Masimo. Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.


SUMMARY OF THE INVENTION

Advantageously, a plethysmographic respiration processor provides respiration rate readings based upon optical properties of pulsatile blood flow. The respiration rate so derived may be used alone or combined with respiration rate derived by various other means including, but not limited to, microphones or other acoustic sensors located to respond to various body sounds; humidity sensors located to respond to inhalation/exhalation moisture; thermistors and photodiodes located to respond to inhalation/exhalation air temperature; capacitance sensors located to respond to inhalation/exhalation air pressure; and venturi effect sensors located to respond to inhalation/exhalation air flow. In a particularly advantageous embodiment, a plethysmographic respiration detector is used in conjunction with an acoustic monitor or combined blood parameter and acoustic monitor, such as a Masimo Rainbow® SET platform and an acoustic respiration rate (RRa™) sensor available from Masimo, so as to improve the accuracy of, robustness of, or otherwise supplement acoustic-derived respiration rate measurements or other acoustic-derived respiration parameters.


One aspect of a plethysmographic respiration processor is responsive to respiration affecting blood volume and a corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of respiration rate. The plethysmographic respiration detector comprises a preprocessor, processors and decision logic. The preprocessor identifies a windowed pleth corresponding to a physiologically acceptable series of plethysmograph waveform pulses. The processors derive various spectrums of the windowed pleth. Each of the processors is configured so that its corresponding spectrum is particularly responsive to a specific respiratory effect on the windowed pleth. The decision logic determines a respiration rate based upon matching features of at least two of the spectrums.


In various embodiments, the processors comprise a baseline processor that inputs the windowed pleth and outputs a “baseline” spectrum. The baseline processor has a first signal conditioner and a first frequency transform. The first signal conditioner generates a first conditioned pleth from the windowed pleth. The first frequency transform inputs the first conditioned pleth and generates the baseline spectrum.


The processors further comprise an amplitude modulation (AM) processor that inputs the windowed pleth and outputs an “AM” spectrum. The AM processor has a second signal conditioner that generates a second conditioned pleth from the windowed pleth. A demodulator AM demodulates the second conditioned pleth to generate a demodulated pleth. A second frequency transform inputs the demodulated pleth and generates the AM spectrum.


The processors further comprise a shape modulation (SM) processor that inputs the windowed pleth and outputs a “SM” spectrum. The SM processor has a third signal conditioner that generates a third conditioned pleth from the windowed pleth. A feature extractor generates a modulated metric from the third conditioned pleth. A third frequency transform generates the SM spectrum from the modulated metric.


The decision logic has a peak detector, a comparator and a respiration rate output. The peak detector operates on at least two of the baseline spectrum, the AM spectrum and the SM spectrum so as to determine local maximums. The comparator determines if there are any local maximums from the at least two of the spectrums that occur at matching frequencies within a predetermined tolerance. A respiration rate output is generated if the comparator finds at least a two-way match. A smoother operates on multiple respiration rate outputs derived over a sliding series of the windowed pleths so as to derive a smoothed respiration rate output. A tested condition rejects the respiration rate output if it differs from the smoothed respiration rate output by more than a predetermined amount.


Another aspect of a respiration rate processor is inputting a plethysmograph waveform, determining a baseline spectrum responsive to a respiratory-induced baseline shift of the plethysmograph waveform, determining an amplitude modulation (AM) spectrum responsive to a respiratory-induced amplitude modulation of the plethysmograph waveform, determining a shape modulation (SM) spectrum responsive to a respiratory-induced shape modulation of the plethysmograph waveform, and matching at least two of the baseline, AM and SM spectrums so as to derive a respiration rate. In an embodiment, determining a baseline spectrum comprises frequency transforming the plethysmograph waveform. In an embodiment, determining an AM spectrum comprises demodulating the plethysmograph waveform so as to generate a demodulated pleth; and frequency transforming the demodulated pleth. In an embodiment, determining a SM spectrum comprises feature extracting the plethysmograph waveform so as to generate a modulated metric and frequency transforming the modulated metric.


In various other embodiments, matching comprises detecting peaks in at least two of the spectrums, comparing the detected peaks so as to find one peak from each of the at least two spectrums occurring at a particular frequency and outputting the particular frequency as the respiration rate. Windowed pleths are defined by a sliding window of acceptable portions of the plethysmograph waveform. The respiration rate output is smoothed based upon a median respiration rate calculated over multiple ones of the windowed pleths. The particular frequency is rejected if it is not within a predetermined difference of the smoothed respiration rate.


A further aspect of a respiration rate processor is a baseline processor, an AM processor, a SM processor and decision logic. The baseline processor identifies a respiration-induced baseline shift in a plethysmograph waveform. The AM processor identifies a respiration-induced amplitude modulation of the plethysmograph waveform. The SM processor identifies a respiration-induced shape modulation of the plethysmograph waveform. The decision logic compares the respiration-induced baseline shift, amplitude modulation and shape modulation so as to derive a respiration rate.


In various embodiments, the baseline processor generates a baseline spectrum from a first frequency transform of the plethysmograph waveform. The AM processor generates an AM spectrum from a second frequency transform of demodulated plethysmograph waveform. The SM processor generates an SM spectrum from a third frequency transform of a modulated metric extracted from the plethysmograph waveform. Decision logic has a peak detector and a comparator. The peak detector determines local maximums in each of the baseline spectrum, AM spectrum and SM spectrum. In an embodiment, the comparator determines a three-way match in the frequency of the local maximums in the spectrums. In an embodiment, the comparator determines a two-way match in the frequency of the local maximums in the spectrums, and a condition for accepting the two-way match compares a respiration rate determined by the two-way match to a smoothed respiration rate.


A further aspect of a plethysmographic respiration processor is responsive to respiratory modulation of a blood volume waveform or corresponding detected intensity waveform measured with an optical sensor at a blood perfused peripheral tissue site so as to provide a measurement of a respiration parameter. A demodulator processes a sensor signal so as to generate a plethysmograph waveform. A pulse processor identifies candidate pulses from the plethysmograph waveform. A pulse modeler identifies physiologically acceptable ones of the candidate pulses. The plethysmographic respiration processor has a feature extractor, a normalizer and a feature analyzer. The feature extractor processes the acceptable pulses so as to calculate pulse features. The normalizer compares the pulse features so as to calculate a pulse parameter. The feature analyzer calculates a respiration parameter from the pulse parameter.


In various embodiments, the pulse features comprise a difference (E) between an acceptable pulse and a triangular pulse estimate; the pulse features comprise an area (A) under a triangular pulse; or the pulse features are calculated with respect to a diastolic (d) portion of an acceptable pulse and a corresponding diastolic portion of a triangular pulse. In various embodiments, the normalizer compares a diastolic difference (Ed) with a diastolic area (Ad) or the normalizer calculates Ed/Ad. In an embodiment, the feature analyzer determines the frequency spectrum of Ed/Ad so as to determine a respiration rate.


Yet another aspect of a plethysmographic respiration processor detects a tissue site response to optical radiation having a plurality of wavelengths, demodulates the response according to wavelength so as to generate a corresponding plurality of plethysmograph waveforms, identifies acceptable pulses from at least one of the waveforms and calculates a respiration parameter from the acceptable pulses. To calculate a respiration parameter, in various embodiments the processor estimates an acceptable pulse with a triangular pulse and determines a systolic portion and a diastolic portion of the acceptable pulse and the triangular pulse; compares the triangular to the acceptable pulse so as to define pulse features; normalizes the pulse features according to the systolic and diastolic portions so as to generate a pulse parameter; or analyzes the pulse parameter to derive a respiration parameter. The comparing may comprise differencing the acceptable pulse and the triangular pulse over the diastolic portion. The analyzing may comprise transforming the pulse parameter to a frequency parameter and outputting a respiration rate according to a maximum of the frequency parameter.


Additional aspects of plethysmographic respiration processor has a pulse input having physiologically acceptable pleth pulses derived from a plethysmograph waveform. A feature extractor extracts pulse features from the pulse input. The pulse features are modulated by respiration. A normalizer calculates a pulse parameter from the relative magnitude of a first one of the pulse features compared with a second one of the pulse features. A feature analyzer calculates a respiration parameter from the pulse parameter.


In various embodiments, the feature extractor may calculate a difference between a triangular pulse estimate and a corresponding pleth pulse. The feature may also calculate an area under a portion of the triangular pulses. The processor may differentiate between a systolic pulse feature and a diastolic pulse feature. The feature extractor may calculate an apex angle of the slope portion of a triangular pulse estimate. The feature analyzer may perform a frequency transform to extract a respiration rate from the pulse parameter.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a block diagram of a plethysmographic respiration processor embodiment;



FIGS. 2A-B are a block diagram of a pre-processor embodiment and a time illustration of a sliding window, respectively;



FIGS. 3A-C are a block diagram of a baseline processor, an intensity versus time graph of a baseline modulated pleth, and a baseline frequency spectrum, respectively;



FIGS. 4A-D are a block diagram of an AM processor, an intensity versus time graph of an AM pleth, and AM pleth frequency spectrum and a demodulated pleth frequency spectrum, respectively;



FIGS. 5A-D are a block diagram of an SM processor, an intensity versus time graph of an SM pleth, and graph of a shape metric versus time; and a shape metric frequency spectrum, respectively;



FIGS. 6A-B are intensity versus time graphs of a shape modulated pulse illustrating area-based shape metrics;



FIGS. 7A-B are intensity versus time graphs of a shape modulated pulse illustrating arc-length shape metrics;



FIG. 8A-D are a block diagram of an FM processor, an intensity versus time graph of an FM pleth, and graph of a dicrotic-notch based FM metric versus time; and a FM metric frequency spectrum, respectively;



FIG. 9 is a block diagram of a pre-processor embodiment;



FIG. 10 is a block diagram of a plethysmographic respiration processor embodiment;



FIGS. 11A-D are a spectrums of a combined baseline shifted and AM modulated pleth; a spectrum of a demodulated baseline shifted and AM modulated pleth; a SM spectrum; and a non-idealized spectrum, respectively;



FIG. 12 is a decision logic flowchart for advantageously deriving a robust value for respiration rate based upon a baseline, an AM and a SM processor operating on an acceptable window of pleths; and



FIG. 13 is a decision logic flowchart for advantageously deriving a robust value for respiration rate based upon a baseline, an AM and a high pass filtered (HPF) SM processor operating on an acceptable window of pleths.



FIG. 14 is a perspective view of a non-invasive physiological parameter measurement system having a monitor and a corresponding optical sensor and incorporating a plethysmographic respiration processor;



FIGS. 15A-B are graphs of light absorption profiles for pulsatile blood perfused tissue and surrounding tissue and an optical sensor detected light intensity, respectively;



FIG. 16 is block diagram of a non-invasive physiological parameter measurement system having a monitor and a corresponding optical sensor and incorporating a plethysmographic respiration processor; and



FIG. 17 is a block diagram of a modulated plethysmograph demodulator.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


FIG. 1 illustrates a plethysmographic respiration processor 100 embodiment having a plethysmograph waveform (pleth) input 101 and a respiration rate (RR) output 104. The pleth respiration processor 100 includes a preprocessor 200, one or more pleth processors 120 and a post processor 130. The pleth 101 is derived from an optical sensor attached to a tissue site, which is in communications with a pulse oximeter or blood parameter monitor, as described with respect to FIGS. 14-17, below. The pre-processor 200 derives acceptable pleths 112, as described in detail with respect to FIGS. 2A-B, below. The pleth processor(s) 120 each operate on acceptable pleths 112 so as to generate respiration-rated parameters 102 responsive to a person's respiration. The pleth processors 120 may operate in the time domain, the frequency domain or a mix of time or frequency domains. Pleth processors 120 are described in detail with respect to FIGS. 3-8, below. The post-processor 130 resolves or otherwise verifies the respiration-related parameters 102 so as to derive a respiration rate and, perhaps, averages, smoothes or otherwise filters that respiration rate so as to generate the respiration rate (RR) 104 output. Advantageously, this optical sensor derived RR may be used to derive a less intrusive measure of respiration rate or used in combination with acoustic, mechanical, electrical, temperature or other sensors and monitors so as to determine a more accurate or robust measure of respiration rate. Although described herein as deriving a respiration rate, a plethysmographic respiration processor 100 output may be similarly expressed as a respiration or a breathing frequency or interval, among others.



FIGS. 2A-B illustrate a pre-processor 200 having a pleth 101 input and generating a conditioned pleth 112, as described below. The pre-processor 200 has a candidate pulse processor 220, a pulse modeler 230, a sliding window 240, a pleth windower 250 and a signal conditioner 260. A single pleth channel is selected from a multiple demodulated pleths 1705 (FIG. 17) as a representative pleth 101 input. In an embodiment, the representative pleth channel corresponds to the IR wavelength channel of a (two wavelength) pulse oximeter.


As shown in FIG. 2A, the pleth 101 is fed into a candidate pulse processor 220 that removes noise and artifacts and identifies the start and end of pulses that conform to various tests of physiological acceptability. In an embodiment, the candidate pulse processor 220 has curvature, low-pass filter and edge finder components that remove waveform features that do not correspond to the steep inflow phase during ventricular systole or the longer outflow phase during diastole, including the characteristic dichrotic notch and miscellaneous waveform curvature changes. Accordingly, the candidate pulse processor 220 identifies “edges” within an input waveform segment that connect a peak and subsequent valley of a pleth pulse. The candidate pulse processor 220 also has delta T, zero crossing, amplitude threshold and slope checks so as to eliminate certain of the edges that were identified by the curvature, filter and edge finder components that do not meet certain conditions. The delta T discards all the edges that are either too slow or too quick to be physiological. The zero crossing check eliminates all edges that do not cross the zero line, such as small bumps that are not peaks or valleys. The amplitude threshold check removes larger “bumps” than the zero crossing check, such as dicrotic notches. The slope check is based on the observation that in a physiological pulse, the ventricular contraction, i.e. descending pulse portion, is steeper than any subsequent trend in the ascending pulse portion. The pulse finder transforms the edges remaining after the various edge checks into candidate pulses 222, which are fed into the pulse modeler 230.


Also shown in FIG. 2A, the pulse modeler 230 takes the candidate pulses 222 and identifies which of these are acceptable pulses 232, which satisfy an internal model for a physiological plethysmographic waveform. Although the candidate pulse processor 220 performs a series of checks on edges, the pulse modeler 230 performs a series of checks on pulse features. The first component of the pulse modeler calculates relevant pulse features. The remainder of the pulse modeler checks these pulse features to identify physiologically acceptable features. The pulse features component extracts three items of information about the input candidate pulses that are needed for downstream processing by the other components of the pulse modeler including pulse starting point, period and signal strength. The downstream components include a max BPM check, a stick model check, an angle check, a ratio check and a signal strength check. The maximum beats-per-minute (max BPM) check discards pulses having a period that is below a minimum number of samples. The stick model check discards pulses where the corresponding waveform does not fit a stick model. The angle check is based on computing the angle of a normalized slope for the ascending portion of a pulse so as to discard pulses that are extremely asymmetric. The ratio check removes pulses in which the ratio between the duration of the ascending pulse portion and the duration of the descending pulse portion is less than a certain threshold. The signal strength check assigns a confidence value to each pulse, based on its signal strength, and low confidence pulses are discarded. A pulse processor 220 and a pulse modeler 230 are described in U.S. Pat. No. 6,463,311 titled Plethysmograph Pulse Recognition Processor, issued Oct. 8, 2002, assigned to Masimo Corporation and incorporated by reference herein.


Further shown in FIGS. 2A-B, the sliding window 240 defines a series of fixed-time-length (T) samples (“windows”) of pleth, where each window 242 is shifted from the previous window by a fixed time interval (Δt) 244. In an embodiment, each window is T=2125 samples (34 sec) in length at 16 msec per sample (62.5 Hz sample rate), where successive windows are shifted by Δt=2 sec. Each window is either accepted 242 or rejected 248 as designated by an acceptable window 242 output. The pleth windower 250 utilizes the acceptable windows 242 designation to accept a corresponding section of the “raw” pleth 101 input and generate a windowed (raw) pleth 252 output. That is, the pre-processor 200 advantageously allows downstream processing to operate directly on the demodulated pleth while discarding those raw pleth sections that are deemed unacceptable, based upon various pleth models and checks as described above. In an embodiment, the signal conditioner 260 demeans/detrends and bandpass filters the windowed pleth 252 to generate a conditioned pleth 112 output. In an embodiment, the bandpass filter is an IIR filter having a 12-240 bpm (beats per minute) passband. In another embodiment described below with respect to FIG. 9, below, a pre-processor 200 generates windowed features from acceptable pulses derived from the pleth 101 input.



FIGS. 3A-B illustrate a baseline processor 300 that derives a “baseline” spectrum Fb 302 responsive to a respiration-induced baseline shift in a pleth. As shown in FIG. 3A, the baseline processor 300 has a conditioned pleth 301 input and generates a corresponding baseline spectrum Fb 302. As shown in FIG. 3B, the conditioned pleth 301 has a pleth period 381 inversely related to pulse rate (PR). Under certain conditions, an individual's respiration induces a cyclical shift in the pleth baseline 382. The cyclical shift period 383 is inversely related to respiration rate (RR). As shown in FIG. 3C, a frequency spectrum 302 of the baseline-shifted pleth 301 includes a relatively large pulse rate (PR) peak 392 and a relatively small respiration rate (RR) peak 391.


In other embodiments, a baseline processor 300 employs a time domain calculation of the conditioned pleth 301 that determines the period 383 of a cyclical baseline shift and hence respiration rate. Such a time domain calculation may be based upon envelope detection of the conditioned pleths 301, such as a curve-fit to the peaks (or valleys) of the pleth pulses. Measurements of a cyclical variation in a plethysmograph baseline are described in U.S. patent application Ser. No. 11/221,411 titled Noninvasive Hypovolemia Monitor, filed Sep. 6, 2005 and published as US 2006/0058691 A1, assigned to Masimo and incorporated by reference herein.



FIGS. 4A-B illustrate an AM processor 400 that derives an “AM” spectrum Fam 402 responsive to a respiration-induced amplitude modulation of the pleth. As shown in FIG. 4A, the AM processor 400 has a conditioned pleth 401 input and generates a corresponding AM spectrum Fam 402 that is responsive to a demodulated pleth 422. In an embodiment, the demodulator 420 squares, low pass filters (LPF) and square-roots the conditioned pleth 401 to generate a demodulated pleth 422. In an embodiment, the frequency transformation 430 utilizes a Hamming window, a chirp-Z FFT algorithm and a magnitude calculation so as to generate an AM spectrum 402 for the demodulated pleth 422.


As shown in FIG. 4B, a pleth 401 has a pleth period 471 inversely related to pulse rate (PR). Under certain conditions, an individual's respiration amplitude modulates (AM) 472 the plethysmograph 401. In particular, the modulation period 473 is inversely related to respiration rate (RR). As shown in FIG. 4C, a spectrum 480 of the pleth 401 includes a pulse rate (PR) peak 481 and respiration sidebands 482, 483 displaced by RR on either side of the PR peak 481. As shown in FIG. 4D a spectrum 402 of the demodulated pleth 422 includes a DC peak 491 resulting from the demodulated pulse rate “carrier” translated to DC and a respiration rate (RR) peak 492 resulting from the demodulated sidebands 482, 483.


An AM processor 400 is described above as demodulating 420 a conditioned pleth 401. In other embodiments, a time domain calculation of the conditioned pleth 401 determines the respiration modulation period 473 and hence the respiration rate. That time domain calculation may be based upon envelope detection of the conditioned pleth 401, such as a curve-fit to the peaks (or valleys) of the plethysmograph or, alternatively, the peak-to-peak variation. Measurements of variation in a plethysmograph envelope are described in U.S. patent application Ser. No. 11/952,940 titled Plethysmograph Variability Processor, filed Dec. 7, 2007 and published as US 2008/0188760 A1, assigned to Masimo and incorporated by reference herein.



FIGS. 5A-D illustrate a shape modulation (SM) processor 500 that derives an “SM” spectrum Fs 502 responsive to a respiration-induced shape modulation of the pleth. As shown in FIG. 5A, the SM processor 500 has a conditioned pleth 501 input and generates a corresponding SM spectrum Fs 502. In an embodiment, the SM processor 500 includes a feature extractor 520, a high pass filter (HPF) 530 and a frequency transform 540. In another embodiment, the SM processor includes the feature extractor 520 and a frequency transform 540, but excludes the high pass filter 530. The feature extractor 520 generates a shape-based modulated metric 522, such as E/A described below. In an embodiment, the HPF 530 is a time domain difference filter that calculates Yn+1−Yn so as to remove an erroneous first (low frequency) peak in the SM spectrum Fs 502. In an embodiment, the frequency transformation 540 utilizes a Hamming window, a chirp-Z FFT algorithm and a magnitude calculation so as to generate the SM spectrum 502 for each windowed conditioned pleth 501.


As shown in FIG. 5B, a pleth 501 has a pleth period 571 inversely related to pulse rate (PR). Under some circumstances, an individual's respiration modulates the shape of each pleth pulse. This modulation may be described in terms of a predefined pleth feature or “shape metric.” In an advantageous embodiment, a shape metric is defined by a difference or “error” E 572 between the diastolic portion of a pleth pulse and its corresponding triangular pulse approximation, normalized by the area A 573 under the triangular pulse approximation.


As shown in FIG. 5C, a respiration-modulated shape metric 522 has a cyclical period 581 inversely related to respiration rate (RR). As shown in FIG. 5D, a spectrum 502 of the modulated shape metric 522 includes a respiration rate (RR) peak 591.


A SM processor 500 is described above as based upon a normalized diastolic error metric (E/A). In other embodiments, shape metrics may be based upon other pulse features such as a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, θd/θs), or shape metrics may be related to the arc length of the diastolic and/or systolic portions of a pleth pulse, to name a few. These and other pulse shapes and features responsive to respiration are also contemplated herein.



FIGS. 6A-B further illustrates pulse shape features that are derived by a feature extractor 520 (FIG. 5A) embodiment. Acceptable pleth pulses 610 are generated by the pre-processor 200 (FIG. 2A), as described above. For convenience of illustration, the inverse of an “intensity” pulse is shown, as described with respect to FIGS. 15A-B, below. The pleth pulse 610 has a peak Y at a time Wand corresponding valleys at times X and Z. The peak and valleys define a triangular pulse 620 XYZ that approximates the pleth pulse 610. Further, the time line WY corresponding to the peak Y divides the pleth pulse 610 into a systolic portion 630 and a diastolic portion 640.


As shown in FIG. 6A, a systolic error Es 631 is defined as the total area between the pleth pulse 610 and the approximate triangular pulse 620 within the systolic portion 630. A diastolic error Ed 641 is defined as the total area between the pleth pulse 610 and the triangular pulse 620 within the diastolic portion 640.


As shown in FIG. 6B, a systolic area As 632 is defined as the total area under the triangular pulse 620 within the systolic portion 630. A diastolic area Ad 642 is defined as the total area under the triangular pulse 620 within the diastolic portion 640. A systolic angle θs 633 is defined as the angle XYW defined by the triangular pulse within the systolic portion 630. A diastolic angle θd 643 is defined as the angle ZYW defined by the triangular pulse within the diastolic portion 640.


Based upon the above-described pulse feature definitions, normalized pulse features may be defined. These may include normalized diastolic pulse features, such as Ed/Ad, corresponding to the diastolic triangular pulse error normalized by the diastolic triangular pulse area. Other normalized diastolic pulse features may include a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, θd/θs).



FIGS. 7A-B illustrate additional pulse shape features. As shown in FIG. 7A, pulse features may be based upon the length of a curve (trace, arc, path or line) portion of a pleth pulse 710. In particular, a diastolic curve length Ld 745 between the pulse peak Y and valley Z is defined in polar coordinates as:









Ld
=



Y
Z





r
2

+



(

dr

d





θ


)

2






d





θ








(

EQ
.




1

)








where r is the distance from W (time corresponding to the peak Y) to any point V along the curve 710 and θ is the angle between r and the time axis WZ. Ld 745 may be similarly defined in Cartesian coordinates. A systolic curve length Ls 735 may be defined in similar fashion. A normalized length pulse feature Ld/Ls may be defined accordingly. In other embodiments, pulse features Ld 745 or Ls 735 may be normalized by the diastolic 640 or systolic 630 areas or angles defined with respect to FIG. 6B, above. In various embodiments, pulse features Ld 745 or Ls 735 also may be normalized by pulse height WY, by diastolic WZ or systolic XW pulse widths, by total pulse width XZ or by mathematical combinations of these measures of pulse height and pulse width to name a few.


As shown in FIG. 7B, pulse shape features may be based upon the curvature of a portion of a pleth pulse 710. In particular, a curvature κ is defined in pedal coordinates as:









κ
=


1
r



dp
dr






(

EQ
.




2

)








where the pedal coordinates of a point V with respect to the pulse 710 and the pedal point W are the radial distance r from W to V and the perpendicular distance p from W to the line t tangent to the pulse 710 at V, as shown. κ may be similarly defined in Cartesian or polar coordinates. Total curvature K of a curve segment between points a and b is then









K
=




a

b




κ


(
s
)



ds






(

EQ
.




3

)








A diastolic curvature Kd 746 or systolic curvature Ks 736 pulse shape feature may be defined accordingly. In other embodiments, a curvature pulse shape feature may be defined according to the absolute value of the maximum and/or minimum curvature of the pulse 710 or pulse segment 730, 740, or the curvature of a particular feature, such as a dicrotic notch. In other embodiments, pulse shape features Kd 746 or Ks 736 may be normalized by the diastolic 640 or systolic 630 areas or angles defined above with respect to FIGS. 6A-B. In various embodiments, pulse features Kd 746 or Ks 736 also may be normalized by pulse height WY, by diastolic WZ or systolic XW pulse widths, by total pulse width XZ or by mathematical combinations of these measures of pulse height and pulse width to name a few. In other embodiments, various normalized systolic and/or diastolic pulse features may be similarly defined.



FIG. 8A-D illustrate an FM processor 800 that derives an “FM” spectrum Ffm 802 responsive to a respiration-induced frequency modulation of the pleth. As shown in FIG. 8A, the FM processor 800 has a conditioned pleth 112 input and generates a corresponding FM spectrum Ffm 802 that is responsive to a demodulated pleth 822. In an embodiment, the demodulator 820 utilizes a metric Δ responsive to the time difference between identifiable epochs of each pleth pulse. In an embodiment, the epochs are based upon a dicrotic notch. In an embodiment, the metric Δ is the time difference between two identifiable portions of a dicrotic notch such as the notch local maximum, local minimum, or mid-point between local maximum and local minimum, to name a few.


As shown in FIG. 8B, a pleth 801 has a pleth period 871 inversely related to pulse rate (PR). Under certain conditions, an individual's respiration frequency modulates (FM) the plethysmograph 801. In particular, the modulation period 881 (FIG. 8C) is inversely related to respiration rate (RR). FIG. 8C illustrates a respiration-modulated FM metric 822 over time. In particular, an FM metric 822, such as the metric A described above, has a cyclical period 881 inversely related to respiration rate (RR). As shown in FIG. 8D, a spectrum 802 of the FM metric 822 includes a respiration rate (RR) peak 891.



FIG. 9 illustrates another pre-processor 900 embodiment having a pleth 101 input and generating a windowed features 962 output. The pre-processor 900 has a candidate pulse processor 220 and pulse modeler 230 that operate on the pleth 101 input so as to generate an acceptable pulses 232 output, as described with respect to FIG. 2A, above. Further, the pre-processor 900 has a time base standard 940, a feature extractor/normalizer 950, and a windowing/outlier rejecter 960. The time base standard 940 inputs acceptable pulses 941 and outputs resized pulses 942. In particular, the time base standard 940 mathematically re-samples the input pulses 941 so that each pulse has the same number of samples. For example, if a standard pulse has 50 samples and an input pulse 941 has 60 samples, then the input pulse 941 sample interval is made larger by 60/50 or 1.2 times so that the resized input pulse width is 50 samples. Similarly, if an input pulse 941 has 40 samples, then the input pulse 941 sample interval is made smaller by 40/50 or 0.8 times so that the resized input pulse width is 50 samples. A resized input pulse is derived by interpolating the original pulse at re-sampled points. For example, a linear interpolation embodiment is used according to the following









y
=



(



y
2

-

y
1




x
2

-

x
1



)



(

x
-

x
1


)


+

y
1






(

EQ
.




4

)








where X2−X1 is the original sample interval; Y1 and Y2 are input pulse 401 values at X1 and X2, respectively; x is a resized sample point between X1 and X2 and y is the resized pulse value at x. In other embodiments, the interpolation is a cubic spline or a polynomial interpolation to name a few.


Also shown in FIG. 9, the feature extractor/normalizer 950 inputs the resized pulses 942 described above and outputs normalized pulse features 952. Pulse features may include one or more of the differences or “errors” E between an acceptable pulse and its corresponding triangular pulse; areas A under the triangular pulse; and apex angles θ of a triangular pulse, to name a few, as described in detail with respect to FIGS. 6-7, above. Pulse features may also distinguish between a steeper-slope portion corresponding to systole S and a shallower-slope portion corresponding to diastole D. Pulse features are normalized by comparing one or more extracted features with one or more other extracted features. In an embodiment, normalized pulse features 952 advantageously include Ed/Ad corresponding to the diastolic triangular pulse error normalized by the diastolic triangular pulse area. Other normalized pulse features 952 may include a diastolic area, error or angle normalized by the corresponding systolic area, error or angle (Ad/As, Ed/Es, θd/θs). These and additional normalized pulse features relating to an acceptable pulse and/or its corresponding triangular pulse are also contemplated herein and described with respect to FIGS. 6-7, above.


Further shown in FIG. 9, the windowing/outlier rejecter 960 inputs the normalized features 952 and outputs windowed features 962. The windowed features 962, in turn, may be frequency transformed or analyzed in the time domain to determine a respiration modulation of the features, as described above. In particular, windowing 960 defines a sample size (window size) of the normalized features 952. The outlier rejector 960 calculates a mean or median of the normalized features 952 falling within the window, defines an acceptable range around the mean or median and rejects normalized features falling outside of that acceptable range.


Window size may be a function of a respiration rate (RR) 964, a heart rate (HR) 966 or both. In particular, HR 966 corresponds to the input pulse 101 frequency and hence determines the time between samples of the normalized features 952. RR 964 corresponds to the number of feature cycles within a window and hence sets a lower limit on the window size in order to resolve the frequency of those feature cycles.


Pulse rates may typically vary from a resting rate of 40-60 BPM for athletes to 60-90 BPM for non-athletes. Maximum heart rates are typically defined as 220−age. Hence, pulse rates might typically range from 50 to 200 BPM, which is a 4:1 variation in time between samples (0.3 sec to 1.2 sec). Respiration rates may typically vary between 12-20 breaths per minute for resting adults to 35-45 breaths per minute for exercising adults. Hence RR may typically range from 10-50 breaths per minute, which is a 5:1 variation in the number of respiration cycles per window. Accordingly, the number of pulse feature samples per respiration cycle may have a 20:1 variation.


Windowing 960 may be fixed or adjustable. Further, successive windows may be overlapping, i.e. a sliding window may be used, or may be adjacent and non-overlapping. A typical window size may range, say, between 15-120 sec. or more. Accordingly, a window size may encompass, say, 20 respiration cycles at 10 breaths per minute over a 120 sec. window to 12 respiration cycles at 50 breaths per minute over a 15 sec. window. In an embodiment, the window size is adaptively adjusted based upon detected RR and PR.



FIG. 10 illustrates a plethysmographic respiration processor 1000 embodiment having a conditioned plethysmograph waveform (pleth) 112 input and a smoothed respiration rate (RRs) 1005 output. The respiration processor 1000 includes parallel processors 1020, decision logic 1100-1300 and a smoother 1030. The conditioned pleth 112 contains pleth sections corresponding to sliding acceptable windows designated by the pre-processor 200 (FIG. 2A), as described above with respect to FIGS. 2A-B. The parallel processors 1020 each operate on conditioned pleth 112 so as to generate frequency spectrums 1022 responsive to respiration rate. The parallel processors 1020 include a baseline processor 300, an amplitude modulation (AM) processor 400, a high pass filtered (HPF) shape modulation (SM) processor 500 and a SM processor 501. In particular, the baseline processor 300 derives a “baseline” spectrum Fb 302 responsive to a respiration-induced baseline shift in a pleth. The baseline processor 300 is described in detail with respect to FIGS. 3A-C, above. The AM processor 400 derives an “AM” spectrum Fam 402 responsive to a respiration-induced amplitude modulation of the pleth. The AM processor 400 is described in detail with respect to FIGS. 4A-D, above. The SM processors 500, 501 derive “SM” spectrums Fs 502, Fs504 each responsive to a respiration-induced shape modulation of the pleth. The SM processors 500, 501 are described in detail with respect to FIGS. 5-7, above.


As described above, the processors 1020 each generate one spectrum 1022 for each sliding window of the conditioned pleth 112. Accordingly, the decision logic 1100-1300 attempts to generate a respiration rate (RR) value for each conditioned pleth 112 window. The decision logic 1100-1300 compares two or more of the spectrums Fb, Fam, Fs and Fs422 so as to calculate a respiration rate (RR) 1004. If the decision logic 1100-1300 cannot determine a RR 1004 value from the spectrums 1022, the corresponding conditioned pleth window 112, is rejected. A smoother 1030 generates a smoothed respiration rate 1005 calculated over multiple respiration rate 1004 values. In an embodiment, the smoother 1030 determines the median value of RR 1004 corresponding to multiple ones of the conditioned pleth windows 112. In an embodiment, the median value is calculated over five conditioned pleth windows 112. The decision logic 1100-1300 is described in detail with respect to FIGS. 11-13, below.



FIGS. 11A-C illustrate the output of the baseline processor 300 (FIG. 10), AM processor 400 (FIG. 10) and SM processor 500 (FIG. 10), respectively, assuming that a conditioned pleth 112 (FIG. 10) exhibits each of a baseline shift, an amplitude modulation and a shape modulation due to respiration. As shown in FIG. 11A, in view of both a respiration-induced baseline shift and AM modulation, the windowed pleth spectrum 1110 is a combination of a baseline shift spectrum 302 (FIG. 3C) and an AM spectrum 402 (FIG. 4D). This combination is also the baseline spectrum Fb 302 (FIG. 3A), i.e. the frequency transform of the conditioned pleth 112. Hence, in this example, the baseline spectrum 1110 has two possible local maximums or “peaks” 1115, 1116. One peak is due to respiration shifting the pleth baseline and one peak is due to respiration amplitude modulating the pleth. However, these peaks cannot be distinguished. In particular, if RR<0.5PR, then peak 1115 is at a frequency corresponding to RR and peak 1116 is at a frequency corresponding to PR-RR. Likewise, if RR is >0.5 PR, then peak 1115 is at a frequency corresponding to PR-RR and peak 1116 is at a frequency corresponding to RR. That is, “twin” peaks 1115, 1116 occur symmetrically on either side of frequency ½ PR, one at frequency RR and one at frequency PR-RR, but the peak corresponding to the respiration rate RR cannot be resolved by the baseline processor 302 (FIG. 10) alone.


As shown in FIG. 11B, in view of both a respiration-induced baseline shift and AM modulation, the AM spectrum Fam 402 (FIG. 10) is a combination of the spectrums of FIG. 3C and FIG. 4C after demodulation. Hence, in this example, the AM processor output 402 (FIG. 10) has two possible local maximums or peaks 1125, 1126. One peak is due to demodulating the pleth corresponding to the spectrum of FIG. 4C, resulting in the spectrum of FIG. 4D. The other peak is due to demodulating the pleth corresponding to the spectrum of FIG. 3C, which translates the pleth fundamental 392 (FIG. 3C) at PR to DC and the respiration-related peak 391 (FIG. 3C) to PR-RR. As with the peaks described with respect to FIG. 11A, these “twin” peaks 1125, 1126 occur symmetrically on either side of ½ PR, but the peak corresponding to the respiration rate RR cannot be resolved by the AM processor 400 (FIG. 10) alone.


As shown in FIG. 11C, the SM spectrum Fs 502 is unaffected by either a baseline shift or by amplitude modulation. In particular, a respiration-induced baseline shift, which shifts the entire pleth waveform up or down, has negligible effect on the error E 572 (FIG. 5B) or the triangular area A 573 (FIG. 5B). Further, although respiration-induced AM increases or decreases the pleth amplitude, this is accounted for by normalizing the error E by the triangular area A. As such, in view of both a respiration-induced baseline shift and AM, the SM spectrum Fs 502 is responsive only to shape modulation, as shown in FIG. 5D, i.e. a single local maximum or peak 1135 occurs at the respiration rate.


As shown in FIGS. 11A-C, ideally respiration rate may be determined by first verifying the existence of twin peaks 1115, 1116 symmetric about 0.5PR in the baseline spectrum 1110 and twin peaks about 0.5PR in the AM spectrum 1120. Second, one twin from each spectrum 1110, 1120 is matched with the single peak in the SM spectrum 1130. For example, a match between peaks 1115 (FIG. 11A), 1125 (FIG. 11B) and 1135 (FIG. 11C) would provide a robust indication of RR. However, pleths from various sensors, monitors and patients may yield spectrums with erroneous peaks due to physiological conditions or artifact. Accordingly, various peaks and matching conditions are utilized by the decision logic to determine RR, as described with respect to FIGS. 12-13, below.


As shown in FIG. 11D, a peak identifying nomenclature 1140 is used in describing decision logic with respect to the baseline spectrum Fb 302 (FIG. 10) and the AM spectrum Fam 402 (FIG. 10). The largest peak in a spectrum is designated {circle around (1)} and its twin designated {circle around (4)}. If the largest peak is the first peak, which is sometimes erroneous, then the second largest peak is designated {circle around (2)} and its twin designated {circle around (5)}. If the largest peak is the last peak, which is also sometimes erroneous, the second largest peak is designated {circle around (3)} and its twin designated {circle around (6)}.



FIG. 12 illustrates the decision logic 1200 for advantageously deriving a robust value for respiration rate based upon each of the baseline 300, AM 400 and SM 500 processors (FIG. 10) operating on a conditioned pleth 112 (FIG. 10). The spectrums Fb, Fam and Fs from these processors are input 1210 into the decision logic 1200. A peak detector 1220 locates the largest peak {circle around (1)} and its twin {circle around (4)} from each of Fb 1110 (FIG. 11A) and Fam 1120 (FIG. 11B) and the largest peak {circle around (1)} from Fs 1130 (FIG. 11C). The comparator 1230 looks for a three-way match from, say, the largest peak from each of the spectrums. This comparison is denoted 1-1-1, designating the largest peaks from the spectrums Fb-Fam-Fs, respectively. If the frequencies of all of these peaks match 1240, within a predetermined error, then that frequency is output as the respiration rate 1250 for that conditioned pleth window 112 (FIG. 10). If there is no match 1240, other combinations 1260, 1266 of peaks of a particular series are compared 1230, such as the largest peak from Fb, the twin to the largest peak from Fam and the largest peak from Fs, denoted 1-4-1. Hence, all of the following combinations are denoted the first series of combinations to try, i.e. series I: 1-1-1; 1-4-1; 4-1-1; 4-4-1.


As shown in FIG. 12, if there are no matches from series I, other series 1270, 1275 having different types of combinations are tried, as explained below. If a particular twin cannot be located, the corresponding series is rejected 1275. If no 3-way matching peaks are found after trying all combinations in each of series I, II, III, IV 1270, then that particular window is rejected 1280 and no respiration rate value is determined that corresponds to that window.


Series II represents a second set of peak comparisons. In some cases, the largest peak {circle around (1)} from Fb or Fam or both may be the first peak, which is often erroneous. As such, comparisons may be made using the second largest peaks {circle around (2)} from Fb and Fam and the corresponding twins {circle around (5)}. The twins in this series are verified to exist, but not used. Accordingly, in an embodiment, the largest peaks {circle around (1)} and the second largest peaks {circle around (2)} are compared in the following combinations: 2-1-1; 1-2-1; 2-2-1.


Series III represents a third set of peak comparisons. In some cases, the largest peak from Fb or Fam or both may be the last peak, which is also often erroneous. As such, comparisons may be made using the second largest peaks {circle around (3)} from Fb and Fam and the corresponding twins {circle around (6)}. Accordingly, in an embodiment, these peaks are compared in the following combinations: 3-3-1; 6-3-1; 3-6-1; 6-6-1.


Series IV represents yet another set of peak comparisons. In some cases, the largest peak from Fs is erroneous. Hence, comparisons may be made using the largest peak from Fs′, designated {circle around (3)}, and the largest peak and corresponding twin from Fb and Fam, designated {circle around (1)} and {circle around (4)}, as noted above. Accordingly, in an embodiment, these peaks are compared with each other in the following combinations: 4-4-3; 4-1-3; 1-4-3; 1-1-3. In other embodiments, other combinations are possible, for example, the twins to the second largest peaks from Fb and Fam, which are designated {circle around (5)}, could be used in various combinations with other designated peaks described above. If all combinations fail to yield a three-way match 1240, then that particular window is rejected 1280.



FIG. 13 illustrates decision logic 1300 for advantageously deriving a robust value for respiration rate based upon a two-way match of the spectrums Fb, Fam and Fs (or Fs′) from each of the baseline 300, AM 400 and shape 500, 501 processors (FIG. 10) plus an additional condition 1390. In an embodiment, decision logic 1300 is used in the event a respiration rate RR 1004 (FIG. 10) cannot be derived from a three-way match of the spectrums Fb, Fam and Fs (or Fs′), as described with respect to FIG. 12, above.


As shown in FIG. 13, in a series V, the largest peaks from Fb and Fs, denoted 1_1 (without utilizing Fam) are compared for a two-way match 1330. If there is a match, an additional condition 1370 must be met. In an embodiment, the condition 1390 is that the matching frequencies of Fb and Fs must be within a predetermined difference of the smoothed respiration rate (RRs) 1005 (FIG. 10). In an embodiment, the predetermined difference is 1 bpm. If so, the matching frequencies are output as the respiration rate RR 1380. If not, the largest peaks from Fam and Fs, denoted _11 (without utilizing Fb) are also compared for a match 1330. If there is a match from this comparison and the additional condition 1370 is met, then the matching frequencies are output as the respiration rate RR 1380. If these combinations are compared without a match 1350, then a series VI is utilized.


Also shown in FIG. 13, in a series VI, the various peaks from Fb and Fam, each denote 1-6, are compared for a two-way match 1330. If there is a match, the additional condition 1370 must be met. If all combinations, e.g. 11, 12, 13 . . . 21, 22, 23 . . . 36, 46, 56 are tried without a match or there is a match but the additional condition is not met, the window is rejected 1360. In other embodiments, other peaks are compared 1330 and other conditions 1390 must be met.



FIG. 14 illustrates a physiological monitoring system 1400 that incorporates a plethysmographic respiration processor 100 (FIG. 1), as described above. The monitoring system 1400 has a monitor 1410, an optical sensor 1420 and an interconnect cable 1430 connecting the monitor 1410 and sensor 1420. The monitoring system 1400 generates physiological parameters that indicate one or more aspects of a person's physical condition, including, advantageously, a plethysmograph-derived respiration rate. The sensor 1420 attaches to a tissue site 10, such as a fingertip, and is capable of irradiating the tissue site 10 with differing wavelengths of light and detecting the light after attenuation by pulsatile blood flow within the tissue site 10. The monitor 1410 communicates with the sensor 1420 via the interconnect cable 1430 to receive one or more detected intensity signals and to derive from those intensity signals one or more physiological parameters. The monitor also has a display 1412 for presenting parameter values, including respiration rate (RR). Controls 1415 set alarm limits, processing modes, display formats and more. An audio transducer 1416 provides alarm sounds, pulse beeps and button press feedback to name a few. Indicators 1418 show monitor status. The display 1412 may include readouts, colored lights or graphics generated by LEOs, LCOs or CRTs to name a few and is capable of displaying indicia representative of calculated physiological parameters, including respiration rate, and waveforms, including plethysmographs. The display 1412 is also capable of showing historical or trending data related to one or more of the measured parameters or combinations of the measured parameters. User I/O may include, for example, push buttons 1415 and indicators 1418. The push buttons may be soft keys with display-indicated functions or dedicated function keys 1415. Other user I/O (not shown) may include keypads, touch screens, pointing devices, voice recognition devices and the like.



FIG. 15A illustrates a light absorption waveform 1501 at an illuminated peripheral tissue site corresponding to a pulsatile blood volume at that site. The peripheral tissue site is illuminated by, and the corresponding absorption is (indirectly) measured by, an optical sensor 1420 (FIG. 14), as described above. A y-axis 1530 represents the total amount of light absorbed by the tissue site, with time shown along an x-axis 1540. The total absorption is represented by layers, including the static absorption layers due to tissue 1532, venous blood 1534 and a baseline of arterial blood 1536. Also shown is a variable absorption layer 1538 due to the pulse-added volume of arterial blood that is used to derive a plethysmograph, as described above and further with respect to FIG. 15B, below. This light absorption waveform 1501 varies as a function of the wavelength of the optical sensor emitted light according to the blood constituency. Indeed, it is this wavelength variation that allows a multi-parameter patient monitor to determine blood hemoglobin components and other blood constituents along with respiration rate characteristics, as described above.


As shown in FIG. 15A, a pulsatile blood volume 1538 is a function of heart stroke volume, pressure gradient, arterial elasticity and peripheral resistance. The ideal pulsatile blood volume waveform displays a broad peripheral flow curve, with a short, steep inflow phase 1516 followed by a 3 to 4 times longer outflow phase 1518. The inflow phase 1516 is the result of tissue distention by the rapid blood volume inflow during ventricular systole. During the outflow phase 1518, blood flow continues into the vascular bed during diastole. The end diastolic baseline 1514 indicates the minimum basal tissue perfusion. During the outflow phase 1518 is a dicrotic notch 1515. Classically, the dicrotic notch 1515 is attributed to closure of the aortic valve at the end of ventricular systole. However, it is also a function of reflection from the periphery of an initial, fast propagating pressure pulse that occurs upon the opening of the aortic valve preceding the arterial flow wave. Pulsatile blood volume varies with physiological properties such as heart stroke, vessel size, elasticity and vascularization, to name a few. Accordingly, the blood flow waveform shape can vary significantly from individual to individual and between tissue sites.



FIG. 15B illustrates a plethysmograph waveform 1502 detected by an optical sensor 1420 (FIG. 14). In particular, detected intensity is shown along the y-axis 1550 versus time shown along the x-axis 1560. The plethysmograph waveform 1502 is a time series of plethysmograph (“pleth”) pulses and relates to the time-varying pulsatile blood volume 1538 (FIG. 15A) measured at a particular location on a person, referred to herein as a “tissue site.” A tissue site can be a fingertip, ear lobe, toe, nose or forehead to name just as few. A person is used herein as the referenced subject of optical sensor measurements, but other living species also have a measurable pleth and are included within the scope of this disclosure.


As shown in FIG. 15B, an optical sensor 1420 (FIG. 14) does not directly detect absorption and, hence, does not directly measure the volume waveform 1538 (FIG. 15A). However, the plethysmograph waveform 1502 is merely an out-of-phase version of the volume profile 1538. Stated differently, the plethysmograph waveform 1502 varies inversely with the pulsatile blood volume 1538. In particular, the peak detected intensity 1554 occurs at minimum volume 1514 and the minimum detected intensity 1552 occurs at maximum volume 1512. Further, a rapid rise in volume during the inflow phase 1516 is reflected in a rapid decline in intensity 1556; and the gradual decline in volume during the outflow phase 1518 is reflected in a gradual increase 1558 in detected intensity. The intensity waveform 1502 also displays a dicrotic notch 1555.



FIG. 16 further illustrates a physiological monitoring system 1600 having an optical sensor 1620 attached to a tissue site 10, a monitor 1610 and an interconnecting sensor cable 1620. The sensor 1620 has emitters 1622, each of which transmit light of a specified wavelength. Drivers 1654, 1655 convert digital control signals into analog drive signals capable of activating the emitters 1622. A front-end 1652, 1653 converts composite analog intensity signal(s) from the detector(s) 1624 into digital data input to a digital signal processor (DSP) 1658. The DSP 1658 may comprise any of a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In an embodiment, the DSP executes firmware 1659 including pre-processors, respiration processors and post processors, such as described with respect to FIGS. 1-13, above.


Also shown in FIG. 16, an instrument manager 1682 may comprise one or more microcontrollers controlling system management, such as monitoring the activity of the DSP 1658. The instrument manager 1682 has an interface port 1683 for monitor communications. In an embodiment, the interface port 1683 has a display driver, an audio driver, user inputs and I/O for driving displays and alarms, responding to buttons and keypads and providing external device input/output communications. In an embodiment, the displays can indicate a variety of physiological parameters 1686 such as respiration rate (RR), pulse rate (PR), plethysmograph (pleth), perfusion index (PI), pleth variability index (PVI), signal quality (IQ) and values for blood constituents including oxygen saturation (SpO2), carboxyhemoglobin (HbCO), methemoglobin (HbMet), total hemoglobin (Hbt) and oxygen content (OC) as well as instrument and sensor status, such as sensor life, to name but a few.



FIG. 17 illustrates a demodulator 1700 having a modulated/multiplexed detector signal 1703 input and demodulated signal 1705 outputs. That is, the demodulator input 1703 is the result of a detector 1624 (FIG. 16) response to N emitter wavelengths 1622 (FIG. 16) that are cyclically turned on and off by emitter drivers 1654 (FIG. 16) so as to illuminate a tissue site with multiple wavelength optical radiation, as is well known in the pulse oximetry art. The digitized detector signal 1703 corresponds to the A/D converter 1657 (FIG. 16) input to the DSP 1658 (FIG. 16). The DSP has demodulator 1700 (preprocessor) firmware 1659 which generates N channels of demodulated signals r1(t), r2(t), . . . , rN(t) 1705 in response. One signal ri(t) corresponding to each emitter wavelength 1622. These demodulated signals are plethysmographs, as described above.


The demodulator 1700 has mixers 1730 and low pass filters 1740 for each channel and demodulating signals di(t) 1704 provided to each mixer 1730. The demodulating signals are linear combinations of (orthogonal) basis functions of the form











d
i



(
t
)


=




j
=
1

M








β
ij

·


ϕ
j



(
t
)








(

EQ
.




5

)








which are derived by approximating the optical response of the emitters to on/off periods of the emitter drivers. M is the number of basis functions needed to approximate such optical responses. ϕj(t) is the jth basis function used by the demodulator. In one embodiment, the basis functions are of the form












ϕ
j



(
t
)


=

sin


(




2

π

T


jt

+


b
j



π
2



)



;


b
j



[

0
,
1

]






(

EQ
.




6

)








where T is the period of the repeating on/off patterns of the emitter drivers. Accordingly, the lowpass filter outputs 1705 are r1(t), r2(t), . . . , rN(t), which are estimates of absorption for each emitter wavelength in view of noise n(t) that is additive to each channel. Plethysmograph demodulators are described in U.S. Pat. No. 5,919,134 titled Method and Apparatus for Demodulating Signals in a Pulse Oximetry System, issued Jul. 6, 1999; U.S. Pat. No. 7,003,338 titled Method and Apparatus for Reducing Coupling Between Signals, issued Feb. 21, 2006; and U.S. patent application Ser. No. 13/037,321 titled Plethysmograph Filter, filed Feb. 28, 2011; all assigned to Masimo Corporation and incorporated by reference herein.


Advantageously, a plethysmographic respiration processor 100 (FIG. 1) is implemented on an advanced pulse oximetry monitor or an advanced blood parameter monitor, as described above. Although a plethysmographic respiration processor is described above with respect to deriving respiration rate from a plethysmograph waveform, in other embodiments, a plethysmographic respiration processor may be used to derive other respiration-related parameters. In a particularly advantageous embodiment, a plethysmographic respiration processor is used in conjunction with an acoustic monitor or combined blood parameter and acoustic monitor so as to improve the accuracy of, robustness of, or otherwise supplement acoustic-derived respiration rate measurements or other acoustic-derived respiration parameters.


A plethysmographic respiration processor has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims herein. One of ordinary skill in art will appreciate many variations and modifications.

Claims
  • 1. A respiration rate detection method comprising: identifying a portion of a plethysmograph waveform which includes a physiologically acceptable series of plethysmograph waveform pulses;deriving, using one or more processors, a plurality of different frequency spectrums from the portion of the plethysmograph waveform using a plurality of different techniques, each of the plurality of different frequency spectrums responsive to at least one respiratory effect on the portion of the plethysmograph waveform and including a plurality of local maximums, the plurality of different frequency spectrums comprising a first frequency spectrum and a second frequency spectrum,wherein the first frequency spectrum is one of: a baseline frequency spectrum responsive to a respiratory-induced baseline shift of the portion of the plethysmograph waveform,an amplitude modulation (AM) frequency spectrum responsive to a respiratory-induced amplitude modulation of the portion of the plethysmograph waveform, anda shape modulation (SM) frequency spectrum responsive to a respiratory-induced shape modulation of the portion of the plethysmograph waveform,wherein second frequency spectrum is different from the first frequency spectrum and is one of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum;determining whether the local maximums of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within a tolerance; andgenerating a respiration rate from determining that at least one local maximum of each of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within the tolerance.
  • 2. The respiration rate detection method of claim 1, further comprising: generating a plurality of respiration rates from portions of the plethysmograph waveform; andderiving a smoothed respiration rate from the plurality of respiration rates and the respiration rate.
  • 3. The respiration rate detection method of claim 2, further comprising rejecting an additional respiration rate in response to determining that the additional respiration rate differs from the smoothed respiration rate by more than an amount.
  • 4. The respiration rate detection method of claim 1, wherein the respiration rate is a frequency of one of the local maximums of the first frequency spectrum.
  • 5. The respiration rate detection method of claim 1, further comprising identifying frequencies of the local maximums of the first frequency spectrum relative to a frequency corresponding to a pulse rate, wherein said determining whether the local maximums of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within the tolerance comprises comparing individual local maximums of the first frequency spectrum and individual local maximums of the second frequency spectrum in an order based at least on the identified frequencies of the local maximums of the first frequency spectrum relative to the frequency corresponding to the pulse rate.
  • 6. The respiration rate detection method of claim 1, wherein said determining whether the local maximums of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within the tolerance comprises comparing individual local maximums of the first frequency spectrum and individual local maximums of the second frequency spectrum in an order based at least on magnitudes of the local maximums of the first frequency spectrum.
  • 7. The respiration rate detection method of claim 1, further comprising outputting the respiration rate for presentation on a display to a user.
  • 8. The respiration rate detection method of claim 1, wherein the first frequency spectrum is the baseline frequency spectrum, and said deriving comprises: generating a conditioned pleth from the portion of the plethysmograph waveform; andgenerating the baseline frequency spectrum from the first conditioned pleth.
  • 9. The respiration rate detection method of claim 1, wherein the first frequency spectrum is the AM frequency spectrum, and said deriving comprises: generating a conditioned pleth from the portion of the plethysmograph waveform;demodulating the conditioned pleth to generate a demodulated pleth; andgenerating the AM frequency spectrum from the demodulated pleth.
  • 10. The respiration rate detection method of claim 1, wherein the first frequency spectrum is the SM frequency spectrum, and said deriving comprises: generating a conditioned pleth from the portion of the plethysmograph waveform;generating a modulated metric from the conditioned pleth; andgenerating the SM frequency spectrum from the modulated metric.
  • 11. The respiration rate detection method of claim 1, wherein the plurality of different frequency spectrums comprises a third frequency spectrum, and further comprising: determining whether the local maximums of the first frequency spectrum, the second frequency spectrum, and the third frequency spectrum occur at matching frequencies within the tolerance; andgenerating the respiration rate from determining that at least one local maximum of each of the first frequency spectrum, the second frequency spectrum, and the third frequency spectrum occur at matching frequencies within the tolerance,wherein third frequency spectrum is different from the first frequency spectrum and the second frequency spectrum, and the third frequency spectrum is one of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum.
  • 12. The respiration rate detection method of claim 11, further comprising: generating a plurality of respiration rates from portions of the plethysmograph waveform; andderiving a smoothed respiration rate from the plurality of respiration rates and the respiration rate.
  • 13. The respiration rate detection method of claim 12, further comprising rejecting an additional respiration rate in response to determining that the additional respiration rate differs from the smoothed respiration rate by more than an amount.
  • 14. The respiration rate detection method of claim 11, wherein the respiration rate is a frequency of one of the local maximums of the first frequency spectrum.
  • 15. The respiration rate detection method of claim 11, further comprising outputting the respiration rate for presentation on a display to a user.
  • 16. The respiration rate detection method of claim 11, wherein the first frequency spectrum is the baseline frequency spectrum, and said deriving comprises: generating a conditioned pleth from the portion of the plethysmograph waveform; andgenerating the baseline frequency spectrum from the first conditioned pleth.
  • 17. The respiration rate detection method of claim 11, wherein the first frequency spectrum is the AM frequency spectrum, and said deriving comprises: generating a conditioned pleth from the portion of the plethysmograph waveform;demodulating the conditioned pleth to generate a demodulated pleth; andgenerating the AM frequency spectrum from the demodulated pleth.
  • 18. The respiration rate detection method of claim 11, wherein the first frequency spectrum is the SM frequency spectrum, and said deriving comprises: generating a conditioned pleth from the portion of the plethysmograph waveform;generating a modulated metric from the conditioned pleth; andgenerating the SM frequency spectrum from the modulated metric.
  • 19. The respiration rate detection method of claim 1, wherein the first frequency spectrum is the baseline frequency spectrum, and the second frequency spectrum is the SM frequency spectrum.
  • 20. The respiration rate detection method of claim 1, wherein the first frequency spectrum is the AM frequency spectrum, and the second frequency spectrum is the SM frequency spectrum.
  • 21. The respiration rate detection method of claim 1, wherein the first frequency spectrum is the baseline frequency spectrum, and the second frequency spectrum is the AM frequency spectrum.
  • 22. The respiration rate detection method of claim 21, further comprising generating the respiration rate from determining that at least one local maximum of each of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within the tolerance and determining that an additional condition is met.
  • 23. A respiration rate detection method comprising: identifying a portion of a plethysmograph waveform which includes a physiologically acceptable series of plethysmograph waveform pulses;deriving, using one or more processors, a plurality of different frequency spectrums from the portion of the plethysmograph waveform using a plurality of different techniques, each of the plurality of different frequency spectrums responsive to at least one respiratory effect on the portion of the plethysmograph waveform and including a plurality of local maximums, the plurality of different frequency spectrums comprising a first frequency spectrum and a second frequency spectrum,wherein the first frequency spectrum is one of: a baseline frequency spectrum responsive to a respiratory-induced baseline shift of the portion of the plethysmograph waveform,an amplitude modulation (AM) frequency spectrum responsive to a respiratory-induced amplitude modulation of the portion of the plethysmograph waveform, anda shape modulation (SM) frequency spectrum responsive to a respiratory-induced shape modulation of the portion of the plethysmograph waveform,wherein second frequency spectrum is different from the first frequency spectrum and is one of the baseline frequency spectrum, the AM frequency spectrum, and the SM frequency spectrum;determining whether the local maximums of the first frequency spectrum and the second frequency spectrum occur at matching frequencies within a tolerance by comparing the local maximums of the first frequency spectrum and the second frequency spectrum until: (1) determining that one local maximum of the first frequency spectrum and one local maximum of the second frequency spectrum occur at matching frequencies within the tolerance; or (2) determining that none of at least two of the local maximums of the first frequency spectrum and none of at least two of the local maximums of the second frequency spectrum occur at matching frequencies within the tolerance; andgenerating a respiration rate in response to determining that one local maximum of the first frequency spectrum and one local maximum of the second frequency spectrum occur at matching frequencies within the tolerance.
  • 24. The respiration rate detection method of claim 23, further comprising generating no respiration rate in response to determining that none of the at least two of the local maximums of the first frequency spectrum and none of the at least two of the local maximums of the second frequency spectrum occur at matching frequencies within the tolerance.
PRIORITY CLAIM TO RELATED PROVISIONAL APPLICATIONS

The present application is a divisional of U.S. patent application Ser. No. 13/076,423, filed Mar. 30, 2011, titled Plethysmographic Respiration Processor, which claims priority benefit under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 61/319,256, filed Mar. 30, 2010, titled Plethysmographic Respiration Processor and U.S. Provisional Patent Application No. 61/364,141, filed Jul. 14, 2010, titled Plethysmographic Respiration Detector; all of the above-cited patent applications are hereby incorporated by reference herein.

US Referenced Citations (777)
Number Name Date Kind
3682161 Alibert Aug 1972 A
4127749 Atoji et al. Nov 1978 A
4326143 Guth et al. Apr 1982 A
4507653 Bayer Mar 1985 A
4537200 Widrow Aug 1985 A
4714341 Hamaguri Dec 1987 A
4848901 Hood, Jr. Jul 1989 A
4884809 Rowan Dec 1989 A
4958638 Sharpe et al. Sep 1990 A
4960128 Gordon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
5033032 Houghtaling Jul 1991 A
5041187 Hink et al. Aug 1991 A
5069213 Polczynski Dec 1991 A
5143078 Mather et al. Sep 1992 A
5163438 Gordon et al. Nov 1992 A
5309922 Schechter et al. May 1994 A
5319355 Russek Jun 1994 A
5337744 Branigan Aug 1994 A
5341805 Stavridi et al. Aug 1994 A
D353195 Savage et al. Dec 1994 S
D353196 Savage et al. Dec 1994 S
5377302 Tsiang Dec 1994 A
5377676 Vari et al. Jan 1995 A
D359546 Savage et al. Jun 1995 S
5431170 Mathews Jul 1995 A
D361840 Savage et al. Aug 1995 S
D362063 Savage et al. Sep 1995 S
5448996 Bellin et al. Sep 1995 A
5452717 Branigan et al. Sep 1995 A
D363120 Savage et al. Oct 1995 S
5456252 Vari et al. Oct 1995 A
5479934 Imran Jan 1996 A
5482036 Diab et al. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5494043 O'Sullivan et al. Feb 1996 A
5533511 Kaspari et al. Jul 1996 A
5534851 Russek Jul 1996 A
5561275 Savage et al. Oct 1996 A
5562002 Lalin Oct 1996 A
5590649 Caro et al. Jan 1997 A
5602924 Durand et al. Feb 1997 A
5632272 Diab et al. May 1997 A
5638403 Birchler et al. Jun 1997 A
5638816 Kiani-Azarbayjany et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645440 Tobler et al. Jul 1997 A
5671191 Gerdt Sep 1997 A
5685299 Diab et al. Nov 1997 A
5724983 Selker et al. Mar 1998 A
D393830 Tobler et al. Apr 1998 S
5743262 Lepper, Jr. et al. Apr 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5782757 Diab et al. Jul 1998 A
5785659 Caro et al. Jul 1998 A
5791347 Flaherty et al. Aug 1998 A
5810734 Caro et al. Sep 1998 A
5819007 Elghazzawi Oct 1998 A
5823950 Diab et al. Oct 1998 A
5830131 Caro et al. Nov 1998 A
5833618 Caro et al. Nov 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5865736 Baker, Jr. et al. Feb 1999 A
5890929 Mills et al. Apr 1999 A
5904654 Wohltmann et al. May 1999 A
5919134 Diab Jul 1999 A
5928156 Krumbiegel Jul 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5995855 Kiani et al. Nov 1999 A
5997343 Mills et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6011986 Diab et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6029665 Berthon-Jones Feb 2000 A
6036642 Diab et al. Mar 2000 A
6045509 Caro et al. Apr 2000 A
6064910 Andersson et al. May 2000 A
6067462 Diab et al. May 2000 A
6081735 Diab et al. Jun 2000 A
6083172 Baker et al. Jul 2000 A
6088607 Diab et al. Jul 2000 A
6110522 Lepper, Jr. et al. Aug 2000 A
6112171 Sugiyama et al. Aug 2000 A
6124597 Shehada Sep 2000 A
6128521 Marro et al. Oct 2000 A
6129675 Jay Oct 2000 A
6138675 Berthon-Jones Oct 2000 A
6139505 Murphy Oct 2000 A
6144868 Parker Nov 2000 A
6151516 Kiani-Azarbayjany et al. Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6168568 Gavriely Jan 2001 B1
6184521 Coffin, IV et al. Feb 2001 B1
6206830 Diab et al. Mar 2001 B1
6229856 Diab et al. May 2001 B1
6232609 Snyder et al. May 2001 B1
6236872 Diab et al. May 2001 B1
6241683 Macklem et al. Jun 2001 B1
6248083 Smith et al. Jun 2001 B1
6253097 Aronow et al. Jun 2001 B1
6254551 Varis Jul 2001 B1
6256523 Diab et al. Jul 2001 B1
6261238 Gavriely Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6285896 Tobler et al. Sep 2001 B1
6301493 Marro et al. Oct 2001 B1
6317627 Ennen et al. Nov 2001 B1
6321100 Parker Nov 2001 B1
6325761 Jay Dec 2001 B1
6331162 Mitchell Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6360114 Diab et al. Mar 2002 B1
6368283 Xu et al. Apr 2002 B1
6371921 Caro et al. Apr 2002 B1
6377829 Al-Ali Apr 2002 B1
6383143 Rost May 2002 B1
6388240 Schulz et al. May 2002 B2
6397091 Diab et al. May 2002 B2
6430437 Marro Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6443907 Mansy et al. Sep 2002 B1
6463311 Diab Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6486588 Doron et al. Nov 2002 B2
6491647 Bridger et al. Dec 2002 B1
6501975 Diab et al. Dec 2002 B2
6505059 Kollias et al. Jan 2003 B1
6515273 Al-Ali Feb 2003 B2
6517497 Rymut et al. Feb 2003 B2
6519487 Parker Feb 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6595316 Cybulski et al. Jul 2003 B2
6597932 Tian et al. Jul 2003 B2
6597933 Kiani et al. Jul 2003 B2
6606511 Ali et al. Aug 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6639668 Trepagnier Oct 2003 B1
6640116 Diab Oct 2003 B2
6643530 Diab et al. Nov 2003 B2
6647280 Bahr et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6654624 Diab et al. Nov 2003 B2
6658276 Kiani et al. Dec 2003 B2
6659960 Derksen et al. Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6671531 Al-Ali et al. Dec 2003 B2
6678543 Diab et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6697656 Al-Ali Feb 2004 B1
6697657 Shehada et al. Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6721582 Trepagnier et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725074 Kastle Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6735459 Parker May 2004 B2
6745060 Diab et al. Jun 2004 B2
6754516 Mannheimer Jun 2004 B2
6760607 Al-Ali Jul 2004 B2
6766038 Sakuma et al. Jul 2004 B1
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6792300 Diab et al. Sep 2004 B1
6813511 Diab et al. Nov 2004 B2
6816741 Diab Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6830711 Mills et al. Dec 2004 B2
6839581 Ei-Solh et al. Jan 2005 B1
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6852083 Caro et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6898452 Al-Ali May 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6931268 Kiani-Azarbayjany et al. Aug 2005 B1
6934570 Kiani et al. Aug 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6943348 Coffin, IV Sep 2005 B1
6950687 Al-Ali Sep 2005 B2
6961598 Diab Nov 2005 B2
6970792 Diab Nov 2005 B1
6979812 Al-Ali Dec 2005 B2
6985764 Mason et al. Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
6999904 Weber et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7015451 Dalke et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7039449 Al-Ali May 2006 B2
7041060 Flaherty et al. May 2006 B2
7044918 Diab May 2006 B2
7067893 Mills et al. Jun 2006 B2
7096052 Mason et al. Aug 2006 B2
7096054 Abdul-Hafiz et al. Aug 2006 B2
7096060 Arand et al. Aug 2006 B2
7132641 Schulz et al. Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7149561 Diab Dec 2006 B2
7186966 Al-Ali Mar 2007 B2
7190261 Al-Ali Mar 2007 B2
7194306 Turcott Mar 2007 B1
7215984 Diab May 2007 B2
7215986 Diab May 2007 B2
7221971 Diab May 2007 B2
7225006 Al-Ali et al. May 2007 B2
7225007 Al-Ali May 2007 B2
RE39672 Shehada et al. Jun 2007 E
7239905 Kiani-Azarbayjany et al. Jul 2007 B2
7245953 Parker Jul 2007 B1
7254429 Schurman et al. Aug 2007 B2
7254431 Al-Ali Aug 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7267652 Coyle et al. Sep 2007 B2
7272425 Al-Ali Sep 2007 B2
7274955 Kiani et al. Sep 2007 B2
D554263 Al-Ali Oct 2007 S
7280858 Al-Ali et al. Oct 2007 B2
7289835 Mansfield et al. Oct 2007 B2
7292883 De Felice et al. Nov 2007 B2
7295866 Al-Ali Nov 2007 B2
7328053 Diab et al. Feb 2008 B1
7332784 Mills et al. Feb 2008 B2
7340287 Mason et al. Mar 2008 B2
7341559 Schulz et al. Mar 2008 B2
7343186 Lamego et al. Mar 2008 B2
D566282 Al-Ali et al. Apr 2008 S
7355512 Al-Ali Apr 2008 B1
7356365 Schurman Apr 2008 B2
7361146 Bharmi et al. Apr 2008 B1
7371981 Abdul-Hafiz May 2008 B2
7373193 Al-Ali et al. May 2008 B2
7373194 Weber et al. May 2008 B2
7376453 Diab et al. May 2008 B1
7377794 Al Ali et al. May 2008 B2
7377899 Weber et al. May 2008 B2
7383070 Diab et al. Jun 2008 B2
7398115 Lynn Jul 2008 B2
7415297 Al-Ali et al. Aug 2008 B2
7428432 Ali et al. Sep 2008 B2
7438683 Al-Ali et al. Oct 2008 B2
7440787 Diab Oct 2008 B2
7454240 Diab et al. Nov 2008 B2
7467002 Weber et al. Dec 2008 B2
7469157 Diab et al. Dec 2008 B2
7471969 Diab et al. Dec 2008 B2
7471971 Diab et al. Dec 2008 B2
7483729 Al-Ali et al. Jan 2009 B2
7483730 Diab et al. Jan 2009 B2
7489958 Diab et al. Feb 2009 B2
7496391 Diab et al. Feb 2009 B2
7496393 Diab et al. Feb 2009 B2
D587657 Al-Ali et al. Mar 2009 S
7499741 Diab et al. Mar 2009 B2
7499835 Weber et al. Mar 2009 B2
7500950 Al-Ali et al. Mar 2009 B2
7509154 Diab et al. Mar 2009 B2
7509494 Al-Ali Mar 2009 B2
7510849 Schurman et al. Mar 2009 B2
7526328 Diab et al. Apr 2009 B2
7530942 Diab May 2009 B1
7530949 Al Ali et al. May 2009 B2
7530955 Diab et al. May 2009 B2
7539533 Tran May 2009 B2
7563110 Al-Ali et al. Jul 2009 B2
7596398 Al-Ali et al. Sep 2009 B2
7618375 Flaherty Nov 2009 B2
D606659 Kiani et al. Dec 2009 S
7647083 Al-Ali et al. Jan 2010 B2
D609193 Al-Ali et al. Feb 2010 S
D614305 Al-Ali et al. Apr 2010 S
7690378 Turcott Apr 2010 B1
RE41317 Parker May 2010 E
7729733 Al-Ali et al. Jun 2010 B2
7734320 Al-Ali Jun 2010 B2
7761127 Al-Ali et al. Jul 2010 B2
7761128 Al-Ali et al. Jul 2010 B2
7764982 Dalke et al. Jul 2010 B2
D621516 Kiani et al. Aug 2010 S
7791155 Diab Sep 2010 B2
7801581 Diab Sep 2010 B2
7822452 Schurman et al. Oct 2010 B2
RE41912 Parker Nov 2010 E
7844313 Kiani et al. Nov 2010 B2
7844314 Al-Ali Nov 2010 B2
7844315 Al-Ali Nov 2010 B2
7865222 Weber et al. Jan 2011 B2
7873497 Weber et al. Jan 2011 B2
7880606 Al-Ali Feb 2011 B2
7880626 Al-Ali et al. Feb 2011 B2
7891355 Al-Ali et al. Feb 2011 B2
7894868 Al-Ali et al. Feb 2011 B2
7899507 Al-Ali et al. Mar 2011 B2
7899518 Trepagnier et al. Mar 2011 B2
7904132 Weber et al. Mar 2011 B2
7909772 Popov et al. Mar 2011 B2
7910875 Al-Ali Mar 2011 B2
7919713 Al-Ali et al. Apr 2011 B2
7937128 Al-Ali May 2011 B2
7937129 Mason et al. May 2011 B2
7937130 Diab et al. May 2011 B2
7941199 Kiani May 2011 B2
7951086 Flaherty et al. May 2011 B2
7957780 Lamego et al. Jun 2011 B2
7962188 Kiani et al. Jun 2011 B2
7962190 Diab et al. Jun 2011 B1
7976472 Kiani Jul 2011 B2
7988637 Diab Aug 2011 B2
7990382 Kiani Aug 2011 B2
7991446 Ali et al. Aug 2011 B2
8000761 Al-Ali Aug 2011 B2
8008088 Bellott et al. Aug 2011 B2
RE42753 Kiani-Azarbayjany et al. Sep 2011 E
8019400 Diab et al. Sep 2011 B2
8028701 Al-Ali et al. Oct 2011 B2
8029765 Bellott et al. Oct 2011 B2
8036727 Schurman et al. Oct 2011 B2
8036728 Diab et al. Oct 2011 B2
8046040 Ali et al. Oct 2011 B2
8046041 Diab et al. Oct 2011 B2
8046042 Diab et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8050728 Al-Ali et al. Nov 2011 B2
RE43169 Parker Feb 2012 E
8118620 Al-Ali et al. Feb 2012 B2
8126528 Diab et al. Feb 2012 B2
8128572 Diab et al. Mar 2012 B2
8130105 Al-Ali et al. Mar 2012 B2
8145287 Diab et al. Mar 2012 B2
8150487 Diab et al. Apr 2012 B2
8175672 Parker May 2012 B2
8180420 Diab et al. May 2012 B2
8182443 Kiani May 2012 B1
8185180 Diab et al. May 2012 B2
8190223 Al-Ali et al. May 2012 B2
8190227 Diab et al. May 2012 B2
8203438 Kiani et al. Jun 2012 B2
8203704 Merritt et al. Jun 2012 B2
8204566 Schurman et al. Jun 2012 B2
8219172 Schurman et al. Jul 2012 B2
8224411 Al-Ali et al. Jul 2012 B2
8228181 Al-Ali Jul 2012 B2
8229533 Diab et al. Jul 2012 B2
8233955 Al-Ali et al. Jul 2012 B2
8244325 Al-Ali et al. Aug 2012 B2
8255026 Al-Ali Aug 2012 B1
8255027 Al-Ali et al. Aug 2012 B2
8255028 Al-Ali et al. Aug 2012 B2
8260577 Weber et al. Sep 2012 B2
8265723 McHale et al. Sep 2012 B1
8274360 Sampath et al. Sep 2012 B2
8301217 Al-Ali et al. Oct 2012 B2
8306596 Schurman et al. Nov 2012 B2
8310336 Muhsin et al. Nov 2012 B2
8315683 Al-Ali et al. Nov 2012 B2
RE43860 Parker Dec 2012 E
8337403 Al-Ali et al. Dec 2012 B2
8346330 Lamego Jan 2013 B2
8353842 Al-Ali et al. Jan 2013 B2
8355766 Macneish, III et al. Jan 2013 B2
8359080 Diab et al. Jan 2013 B2
8364223 Al-Ali et al. Jan 2013 B2
8364226 Diab et al. Jan 2013 B2
8374665 Lamego Feb 2013 B2
8385995 Al-Ali et al. Feb 2013 B2
8385996 Smith et al. Feb 2013 B2
8388353 Kiani et al. Mar 2013 B2
8399822 Al-Ali Mar 2013 B2
8401602 Kiani Mar 2013 B2
8405608 Al-Ali et al. Mar 2013 B2
8414499 Al-Ali et al. Apr 2013 B2
8418524 Al-Ali Apr 2013 B2
8423106 Lamego et al. Apr 2013 B2
8428967 Olsen et al. Apr 2013 B2
8430817 Al-Ali et al. Apr 2013 B1
8437825 Dalvi et al. May 2013 B2
8455290 Siskavich Jun 2013 B2
8457703 Al-Ali Jun 2013 B2
8457707 Kiani Jun 2013 B2
8463349 Diab et al. Jun 2013 B2
8466286 Bellot et al. Jun 2013 B2
8471713 Poeze et al. Jun 2013 B2
8473020 Kiani et al. Jun 2013 B2
8478538 McGonigle et al. Jul 2013 B2
8483787 Al-Ali et al. Jul 2013 B2
8489364 Weber et al. Jul 2013 B2
8498684 Weber et al. Jul 2013 B2
8504128 Blank et al. Aug 2013 B2
8509867 Workman et al. Aug 2013 B2
8515509 Bruinsma et al. Aug 2013 B2
8523781 Al-Ali Sep 2013 B2
8529301 Al-Ali et al. Sep 2013 B2
8532727 Ali et al. Sep 2013 B2
8532728 Diab et al. Sep 2013 B2
D692145 Al-Ali et al. Oct 2013 S
8547209 Kiani et al. Oct 2013 B2
8548548 Al-Ali Oct 2013 B2
8548549 Schurman et al. Oct 2013 B2
8548550 Al-Ali et al. Oct 2013 B2
8560032 Al-Ali et al. Oct 2013 B2
8560034 Diab et al. Oct 2013 B1
8570167 Al-Ali Oct 2013 B2
8570503 Vo et al. Oct 2013 B2
8571617 Reichgott et al. Oct 2013 B2
8571618 Lamego et al. Oct 2013 B1
8571619 Al-Ali et al. Oct 2013 B2
8577431 Lamego et al. Nov 2013 B2
8581732 Al-Ali et al. Nov 2013 B2
8584345 Al-Ali et al. Nov 2013 B2
8588880 Abdul-Hafiz et al. Nov 2013 B2
8597274 Sloan Dec 2013 B2
8600467 Al-Ali et al. Dec 2013 B2
8606342 Diab Dec 2013 B2
8622902 Woehrle Jan 2014 B2
8626255 Al-Ali et al. Jan 2014 B2
8630691 Lamego et al. Jan 2014 B2
8634889 Al-Ali et al. Jan 2014 B2
8641631 Sierra et al. Feb 2014 B2
8652060 Al-Ali Feb 2014 B2
8663107 Kiani Mar 2014 B2
8666468 Al-Ali Mar 2014 B1
8667967 Al-Ali et al. Mar 2014 B2
8670811 O'Reilly Mar 2014 B2
8670814 Diab et al. Mar 2014 B2
8676286 Weber et al. Mar 2014 B2
8682407 Al-Ali Mar 2014 B2
RE44823 Parker Apr 2014 E
RE44875 Kiani et al. Apr 2014 E
8700112 Kiani Apr 2014 B2
8706179 Parker Apr 2014 B2
8712494 MacNeish, III et al. Apr 2014 B1
8718735 Lamego et al. May 2014 B2
8718737 Diab et al. May 2014 B2
8718738 Blank et al. May 2014 B2
8720249 Al-Ali May 2014 B2
8721541 Al-Ali et al. May 2014 B2
8721542 Al-Ali et al. May 2014 B2
8723677 Kiani May 2014 B1
8740792 Kiani et al. Jun 2014 B1
8754776 Poeze et al. Jun 2014 B2
8755856 Diab et al. Jun 2014 B2
8755872 Marinow Jun 2014 B1
8761850 Lamego Jun 2014 B2
8764671 Kiani Jul 2014 B2
8768423 Shakespeare et al. Jul 2014 B2
8771204 Telfort et al. Jul 2014 B2
8777634 Kiani et al. Jul 2014 B2
8781543 Diab et al. Jul 2014 B2
8781544 Al-Ali et al. Jul 2014 B2
8781549 Al-Ali et al. Jul 2014 B2
8788003 Schurman et al. Jul 2014 B2
8792949 Baker Jul 2014 B2
8821397 Al-Ali et al. Sep 2014 B2
8821415 Al-Ali et al. Sep 2014 B2
8830449 Lamego et al. Sep 2014 B1
8831700 Schurman et al. Sep 2014 B2
8840549 Al-Ali et al. Sep 2014 B2
8847740 Kiani et al. Sep 2014 B2
8849365 Smith et al. Sep 2014 B2
8852094 Al-Ali et al. Oct 2014 B2
8852994 Wojtczuk et al. Oct 2014 B2
8868147 Stippick et al. Oct 2014 B2
8868150 Al-Ali et al. Oct 2014 B2
8870792 Al-Ali et al. Oct 2014 B2
8886271 Kiani et al. Nov 2014 B2
8888539 Al-Ali et al. Nov 2014 B2
8888708 Diab et al. Nov 2014 B2
8892180 Weber et al. Nov 2014 B2
8897847 Al-Ali Nov 2014 B2
8909310 Lamego Dec 2014 B2
8911377 Al-Ali Dec 2014 B2
8912909 Al-Ali et al. Dec 2014 B2
8920317 Al-Ali et al. Dec 2014 B2
8921699 Al-Ali et al. Dec 2014 B2
8922382 Al-Ali et al. Dec 2014 B2
8929964 Al-Ali et al. Jan 2015 B2
8942777 Diab et al. Jan 2015 B2
8948834 Diab et al. Feb 2015 B2
8948835 Diab Feb 2015 B2
8965471 Lamego Feb 2015 B2
8983564 Al-Ali Mar 2015 B2
8989831 Al-Ali et al. Mar 2015 B2
8996085 Kiani et al. Mar 2015 B2
8998809 Kiani Apr 2015 B2
9028429 Telfort et al. May 2015 B2
9037207 Al-Ali et al. May 2015 B2
9060721 Reichgott et al. Jun 2015 B2
9066666 Kiani Jun 2015 B2
9072474 Al-Ali et al. Jul 2015 B2
9078560 Schurman et al. Jul 2015 B2
9084569 Weber et al. Jul 2015 B2
9095316 Welch et al. Aug 2015 B2
9106038 Telfort et al. Aug 2015 B2
9107625 Telfort et al. Aug 2015 B2
9107626 Al-Ali et al. Aug 2015 B2
9113831 Al-Ali Aug 2015 B2
9113832 Al-Ali Aug 2015 B2
9119595 Lamego Sep 2015 B2
9131881 Diab et al. Sep 2015 B2
9131882 Al-Ali et al. Sep 2015 B2
9131883 Al-Ali Sep 2015 B2
9131917 Telfort et al. Sep 2015 B2
9135398 Kaib Sep 2015 B2
9138180 Coverston et al. Sep 2015 B1
9138182 Al-Ali et al. Sep 2015 B2
9138192 Weber et al. Sep 2015 B2
9142117 Muhsin et al. Sep 2015 B2
9153112 Kiani et al. Oct 2015 B1
9153121 Kiani et al. Oct 2015 B2
9161696 Al-Ali et al. Oct 2015 B2
9161713 Al-Ali et al. Oct 2015 B2
9167995 Lamego et al. Oct 2015 B2
9176141 Al-Ali et al. Nov 2015 B2
9186102 Bruinsma et al. Nov 2015 B2
9192312 Al-Ali Nov 2015 B2
9192329 Al-Ali Nov 2015 B2
9192351 Telfort et al. Nov 2015 B1
9195385 Al-Ali et al. Nov 2015 B2
9211072 Kiani Dec 2015 B2
9211095 Al-Ali Dec 2015 B1
9218454 Kiani et al. Dec 2015 B2
9220440 Addison et al. Dec 2015 B2
9226696 Kiani Jan 2016 B2
9241662 Al-Ali et al. Jan 2016 B2
9245668 Vo et al. Jan 2016 B1
9259185 Abdul-Hafiz et al. Feb 2016 B2
9267572 Barker et al. Feb 2016 B2
9277880 Poeze et al. Mar 2016 B2
9289167 Diab et al. Mar 2016 B2
9295421 Kiani et al. Mar 2016 B2
9307928 Al-Ali et al. Apr 2016 B1
9323894 Kiani Apr 2016 B2
9326712 Kiani May 2016 B1
9333316 Kiani May 2016 B2
9339220 Lamego et al. May 2016 B2
9341565 Lamego et al. May 2016 B2
9351673 Diab et al. May 2016 B2
9351675 Al-Ali et al. May 2016 B2
9364181 Kiani et al. Jun 2016 B2
9368671 Wojtczuk et al. Jun 2016 B2
9370325 Al-Ali et al. Jun 2016 B2
9370326 McHale et al. Jun 2016 B2
9370335 Al-Ali et al. Jun 2016 B2
9375185 Ali et al. Jun 2016 B2
9378637 Kaib Jun 2016 B2
9386953 Al-Ali Jul 2016 B2
9386961 Al-Ali et al. Jul 2016 B2
9392945 Al-Ali et al. Jul 2016 B2
9397448 Al-Ali et al. Jul 2016 B2
9408542 Kinast et al. Aug 2016 B1
9436645 Al-Ali et al. Sep 2016 B2
9445759 Lamego et al. Sep 2016 B1
9466919 Kiani et al. Oct 2016 B2
9474474 Lamego et al. Oct 2016 B2
9480422 Al-Ali Nov 2016 B2
9480435 Olsen Nov 2016 B2
9492110 Al-Ali et al. Nov 2016 B2
9510779 Poeze et al. Dec 2016 B2
9517024 Kiani et al. Dec 2016 B2
9532722 Lamego et al. Jan 2017 B2
9538949 Al-Ali et al. Jan 2017 B2
9538980 Telfort et al. Jan 2017 B2
9549696 Lamego et al. Jan 2017 B2
9554737 Schurman et al. Jan 2017 B2
9560996 Kiani Feb 2017 B2
9560998 Al-Ali et al. Feb 2017 B2
9566019 Al-Ali et al. Feb 2017 B2
9579039 Jansen et al. Feb 2017 B2
9591975 Dalvi et al. Mar 2017 B2
9622693 Diab Apr 2017 B2
9659475 Kaib May 2017 B2
9724016 Al-Ali et al. Aug 2017 B1
20010002206 Diab et al. May 2001 A1
20020193670 Garfield et al. Dec 2002 A1
20030015368 Cybulski et al. Jan 2003 A1
20030065269 Vetter Apr 2003 A1
20030076494 Bonin et al. Apr 2003 A1
20030158466 Lynn et al. Aug 2003 A1
20030163033 Dekker et al. Aug 2003 A1
20030163054 Dekker Aug 2003 A1
20040010202 Nakatani Jan 2004 A1
20040059203 Guerrero Mar 2004 A1
20040133087 Ali et al. Jul 2004 A1
20040158162 Narimatsu Aug 2004 A1
20040225332 Gebhardt Nov 2004 A1
20050027205 Tarassenko et al. Feb 2005 A1
20050048456 Chefd'hotel et al. Mar 2005 A1
20050070774 Addison et al. Mar 2005 A1
20050107699 Loftman May 2005 A1
20050116820 Goldreich Jun 2005 A1
20050199056 Strong Sep 2005 A1
20060047215 Newman et al. Mar 2006 A1
20060149144 Lynn et al. Jul 2006 A1
20060155206 Lynn Jul 2006 A1
20060155207 Lynn et al. Jul 2006 A1
20060161071 Lynn et al. Jul 2006 A1
20060189880 Lynn et al. Aug 2006 A1
20060195041 Lynn et al. Aug 2006 A1
20060235324 Lynn Oct 2006 A1
20060238333 Welch et al. Oct 2006 A1
20060241510 Halperin et al. Oct 2006 A1
20060258921 Addison Nov 2006 A1
20070093721 Lynn et al. Apr 2007 A1
20070129643 Kwok et al. Jun 2007 A1
20070129647 Lynn Jun 2007 A1
20070135725 Hatlestad Jun 2007 A1
20070149860 Lynn et al. Jun 2007 A1
20070185397 Govari et al. Aug 2007 A1
20070239057 Pu et al. Oct 2007 A1
20070282212 Sierra et al. Dec 2007 A1
20080013747 Tran Jan 2008 A1
20080039735 Hickerson Feb 2008 A1
20080071185 Beck et al. Mar 2008 A1
20080076972 Dorogusker et al. Mar 2008 A1
20080119716 Boric-Lubecke et al. May 2008 A1
20080161878 Tehrani et al. Jul 2008 A1
20080188733 Al-Ali Aug 2008 A1
20080188760 Al-Ali Aug 2008 A1
20080218153 Patel et al. Sep 2008 A1
20080275349 Halperin et al. Nov 2008 A1
20080304580 Ichiyama Dec 2008 A1
20090018429 Saliga et al. Jan 2009 A1
20090018453 Banet et al. Jan 2009 A1
20090093687 Telfort et al. Apr 2009 A1
20090112096 Tamura Apr 2009 A1
20090167332 Forbes Jul 2009 A1
20090187065 Basinger Jul 2009 A1
20090240119 Schwaibold et al. Sep 2009 A1
20090247848 Baker Oct 2009 A1
20090247984 Lamego et al. Oct 2009 A1
20090275844 Al-Ali Nov 2009 A1
20090299157 Telfort et al. Dec 2009 A1
20100004518 Vo et al. Jan 2010 A1
20100004552 Zhang et al. Jan 2010 A1
20100016682 Schluess et al. Jan 2010 A1
20100016693 Addison Jan 2010 A1
20100030040 Poeze et al. Feb 2010 A1
20100204550 Heneghan Aug 2010 A1
20100261979 Kiani Oct 2010 A1
20100274099 Telfort et al. Oct 2010 A1
20100295686 Sloan Nov 2010 A1
20100298661 McCombie et al. Nov 2010 A1
20100298730 Taressenko et al. Nov 2010 A1
20100324377 Woehrle Dec 2010 A1
20110001605 Kiani Jan 2011 A1
20110009710 Kroeger et al. Jan 2011 A1
20110040713 Colman Feb 2011 A1
20110074409 Stoughton Mar 2011 A1
20110082711 Poeze et al. Apr 2011 A1
20110105854 Kiani et al. May 2011 A1
20110118573 McKenna May 2011 A1
20110125060 Telfort et al. May 2011 A1
20110172551 Al-Ali et al. Jul 2011 A1
20110172561 Kiani et al. Jul 2011 A1
20110196211 Al-Ali et al. Aug 2011 A1
20110208015 Welch et al. Aug 2011 A1
20110209915 Telfort et al. Sep 2011 A1
20110213212 Al-Ali Sep 2011 A1
20110213271 Telfort et al. Sep 2011 A1
20110213272 Telfort et al. Sep 2011 A1
20110213273 Telfort et al. Sep 2011 A1
20110213274 Telfort et al. Sep 2011 A1
20110230733 Al-Ali et al. Sep 2011 A1
20110237911 Lamego et al. Sep 2011 A1
20120016255 Masuo Jan 2012 A1
20120059267 Lamego et al. Mar 2012 A1
20120101344 Desjardins Apr 2012 A1
20120116175 Al-Ali et al. May 2012 A1
20120179006 Jansen et al. Jul 2012 A1
20120209082 Al-Ali Aug 2012 A1
20120209084 Olsen et al. Aug 2012 A1
20120227739 Kiani Sep 2012 A1
20120253140 Addison et al. Oct 2012 A1
20120262298 Bohm Oct 2012 A1
20120283524 Kiani et al. Nov 2012 A1
20120296178 Lamego et al. Nov 2012 A1
20120319816 Al-Ali Dec 2012 A1
20120330112 Lamego et al. Dec 2012 A1
20130023775 Lamego et al. Jan 2013 A1
20130041591 Lamego Feb 2013 A1
20130045685 Kiani Feb 2013 A1
20130046204 Lamego Feb 2013 A1
20130060147 Welch et al. Mar 2013 A1
20130096405 Garfio Apr 2013 A1
20130096936 Sampath et al. Apr 2013 A1
20130109935 Al-Ali et al. May 2013 A1
20130128690 Gopalan May 2013 A1
20130162433 Muhsin et al. Jun 2013 A1
20130190581 Al-Ali et al. Jul 2013 A1
20130190595 Oraevsky Jul 2013 A1
20130197328 Diab et al. Aug 2013 A1
20130243021 Siskavich Sep 2013 A1
20130253334 Al-Ali et al. Sep 2013 A1
20130274571 Diab et al. Oct 2013 A1
20130296672 O'Neil et al. Nov 2013 A1
20130317370 Dalvi et al. Nov 2013 A1
20130324808 Al-Ali et al. Dec 2013 A1
20130331670 Kiani Dec 2013 A1
20130338461 Lamego et al. Dec 2013 A1
20140012100 Al-Ali et al. Jan 2014 A1
20140025306 Weber et al. Jan 2014 A1
20140034353 Al-Ali et al. Feb 2014 A1
20140051953 Lamego et al. Feb 2014 A1
20140058230 Abdul-Hafiz et al. Feb 2014 A1
20140066783 Kiani et al. Mar 2014 A1
20140077956 Sampath et al. Mar 2014 A1
20140081100 Muhsin et al. Mar 2014 A1
20140081175 Telfort Mar 2014 A1
20140094667 Schurman et al. Apr 2014 A1
20140100434 Diab et al. Apr 2014 A1
20140114199 Lamego et al. Apr 2014 A1
20140120564 Workman et al. May 2014 A1
20140121482 Merritt et al. May 2014 A1
20140121483 Kiani May 2014 A1
20140127137 Bellott et al. May 2014 A1
20140128696 Al-Ali May 2014 A1
20140128699 Al-Ali et al. May 2014 A1
20140129702 Lamego et al. May 2014 A1
20140135588 Al-Ali et al. May 2014 A1
20140142401 Al-Ali et al. May 2014 A1
20140142402 Al-Ali et al. May 2014 A1
20140163344 Al-Ali Jun 2014 A1
20140163402 Lamego et al. Jun 2014 A1
20140166076 Kiani et al. Jun 2014 A1
20140171763 Diab Jun 2014 A1
20140180038 Kiani et al. Jun 2014 A1
20140180154 Sierra et al. Jun 2014 A1
20140194709 Al-Ali et al. Jul 2014 A1
20140194711 Al-Ali Jul 2014 A1
20140194766 Al-Ali et al. Jul 2014 A1
20140206963 Al-Ali Jul 2014 A1
20140213864 Abdul-Hafiz et al. Jul 2014 A1
20140243627 Diab et al. Aug 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140275808 Poeze et al. Sep 2014 A1
20140275835 Lamego et al. Sep 2014 A1
20140275871 Lamego et al. Sep 2014 A1
20140275872 Merritt et al. Sep 2014 A1
20140275881 Lamego et al. Sep 2014 A1
20140288400 Diab et al. Sep 2014 A1
20140296664 Bruinsma et al. Oct 2014 A1
20140303520 Telfort et al. Oct 2014 A1
20140309506 Lamego et al. Oct 2014 A1
20140316228 Blank et al. Oct 2014 A1
20140323825 Al-Ali et al. Oct 2014 A1
20140330092 Al-Ali et al. Nov 2014 A1
20140330098 Merritt et al. Nov 2014 A1
20140330099 Al-Ali et al. Nov 2014 A1
20140333440 Kiani Nov 2014 A1
20140336481 Shakespeare et al. Nov 2014 A1
20140343436 Kiani Nov 2014 A1
20150018650 Al-Ali et al. Jan 2015 A1
Foreign Referenced Citations (30)
Number Date Country
2262236 Apr 2008 CA
0716628 Dec 1998 EP
0659058 Jan 1999 EP
1207536 May 2002 EP
2358546 Nov 1999 GB
6214898 Jan 1987 JP
01-309872 Jun 1998 JP
10-155755 Jun 1998 JP
2001-50713 May 1999 JP
2003-329719 Nov 2003 JP
WO 1994005207 Mar 1994 WO
WO 1994013207 Jun 1994 WO
WO 1995029632 Nov 1995 WO
WO 1999053277 Oct 1999 WO
WO 2000010462 Mar 2000 WO
WO 2001034033 May 2001 WO
WO 2001078059 Oct 2001 WO
WO 2001097691 Dec 2001 WO
WO 2002003042 Jan 2002 WO
WO 2003058646 Jul 2003 WO
WO 2003087737 Oct 2003 WO
WO 2004000111 Dec 2003 WO
WO 2004004411 Jan 2004 WO
WO 2005096931 Oct 2005 WO
WO 2005099562 Oct 2005 WO
WO 2008017246 Feb 2008 WO
WO 2008080469 Jul 2008 WO
WO 2008148172 Dec 2008 WO
WO 2009093159 Jul 2009 WO
WO 2009137524 Nov 2009 WO
Non-Patent Literature Citations (21)
Entry
U.S. Appl. No. 12/905,384, filed Oct. 10, 2010, Al-Ali et al.
U.S. Appl. No. 12/905,449, filed Oct. 15, 2010, Al-Ali et al.
U.S. Appl. No. 12/905,489, filed Oct. 15, 2010, Weber et al.
Analog Devices, 12-Bit Serial Input Multiplying D/A Converter, Product Data Sheet, 2000.
Chambrin, M-C.; “Alarms in the intensive care unit: how can the number of false alarms be reduced?”; Critical Care Aug. 2001, vol. 5 No. 4; p. 1-5.
Eldor et al., “A device for monitoring ventilation during anesthesia; the paratracheal audible respiratory monitor”, Canadian Journal of Anesthesia, 1990, vol. 9, No. 1, p. 95-98.
Gorges, M. et al; “Improving Alarm Performance in the Medical Intensive Care Unit Using Delays and Clinical Context”; Technology, Computing, and Simulation; vol. 108, No. 5, May 2009; p. 1546-1552.
Imhoff, M. et al; “Alarm Algorithms in Critical Care Monitoring”; Anesth Analg 2006;102:1525-37.
International Search Report & Written Opinion, PCT Application PCT/US2010/052758, dated Feb. 10, 2011; 12 pages.
International Search Report & Written Opinion, PCT Application PCT/US2010/058981, dated Feb. 17, 2011; 11 pages.
International Search Report and Written Opinion issued in application No. PCT/US2010/052756 dated Feb. 6, 2012.
International Search Report, PCT Application PCT/CA2003/000536, dated Dec. 11, 2003; 2 pages.
International Search Report, PCT Application PCT/US2009/069287, dated Mar. 30, 2010; 7 pages.
Japanese Office Action for JP Application No. 2007-506626 dated Mar. 1, 2011.
Sierra et al., Monitoring Respiratory Rate Based on Tracheal Sounds. First Experiences, Proceedings of the 26th Annual Int'l Conf. of the IEEE EMBS (Sep. 2004), 317-320.
Watt, R. C.; “Alarms and Anesthesia. Challenges in the design of Intelligent systems for Patient Monitoring”; IEEE Engineering in Medicine and biology; Dec. 1993, p. 34-41.
Welch Allyn, ECG ASIC, Product Data Sheet, 2001.
Supplementary Partial European Search Report for International Application No. 05732095.4, dated Jun. 26, 2009 in 4 pages.
Stewart, C., Larson, V., “Detection and classification of acoustic signals from fixed-wing aircraft,” Systems Engineering, CH3051-0/91/0000-0025, IEEE, 1991.
Theimer et al., “Definitions of audio features for music content description”, Algorithm Engineering Report TR08-2-001, Feb. 2008.
Johnston, Development of a Signal Processing Library for Extraction of Sp02, HR, HRV, and RR from Photoplethysmographic Waveforms, Thesis: Degree of Master of Science, Worcester Polytechnic Institute, date of presentation/defense Jul. 17, 2006, date listed Jul. 27, 2006.
Related Publications (1)
Number Date Country
20160287090 A1 Oct 2016 US
Provisional Applications (2)
Number Date Country
61319256 Mar 2010 US
61364141 Jul 2010 US
Divisions (1)
Number Date Country
Parent 13076423 Mar 2011 US
Child 15095912 US